

**Alastair J.J. Wood**

**Address:** Room 550 RRB  
23<sup>rd</sup> Ave S at Pierce Ave  
Vanderbilt University School of Medicine  
Nashville, Tennessee 37232-6602

**Telephone:** (615) 343-8701  
**Fax:** (615) 343-2551

**E-Mail** [Alastair.Wood@vanderbilt.edu](mailto:Alastair.Wood@vanderbilt.edu)

**Citizenship:** United States

**Married:** .....

.....  
.....  
.....  
.....

**Children:** .....  
.....

**Present Appointments:**

Associate Dean  
Vanderbilt University, Nashville, Tennessee  
Professor of Medicine (with tenure)  
Professor of Pharmacology (with tenure)  
Vanderbilt University, Nashville, Tennessee

Attending Physician, Vanderbilt University Hospital, Nashville, Tennessee

**Honors and Awards**

Association of American Physicians (AAP)  
American Society for Clinical Investigation (ASCI)  
Ernest W. Goodpasture Award for Research  
Honorary Fellow, American Gynecological and Obstetrical Society (AGOS)  
Henry Christian AFRC Award for Excellence in Research, 1991  
Fellow, American College of Physicians  
Fellow, Royal College of Physicians, London  
Fellow, Royal College of Physicians, Edinburgh  
Best Doctors in America  
Fellow-Council for High Blood Pressure Research; American Heart Association  
Pharmaceutical Manufacturer's Association Foundation Faculty Development Award in  
Clinical Pharmacology  
Merck Sharp and Dohme International Fellow in Clinical Pharmacology  
William McCunn Traveling Fellowship

Dr. R.D. Campbell Memorial Prize  
Sir James McKenzie Prize

**Editorial Boards:**

**New England Journal of Medicine** X **Editorial Board**, 2004-Present  
X "Drug Therapy Series" - **Editor**, 1992B2004  
X "Drug Therapy Series" - **Associate Editor**, 1985B1991  
**Clinical Pharmacology and Therapeutics (Editorial Board)**  
**Biopharmaceutics & Drug Disposition (Editorial Board)**  
**British Journal of Clinical Pharmacology (Executive Editorial Board)**

**Food and Drug Administration**

Member, Nonprescription Drugs Advisory Committee (2001-Present)  
Member, Cardiovascular and Renal Drugs Advisory Committee (1992B1996)

**National Institutes of Health Study Section**

Member Gerontology and Geriatrics Study Section (1984B1988)  
**Chairman** Gerontology and Geriatrics Study Section (1988B1989)

**AAMC**

Task Force on Conflicts of Interest--Member

**National Institutes of Health (NHLBI)**

Member NHLBI Task Force on HypertensionXClinical Investigation Study Group (1990)

**United States Pharmacopoeial (USP) Convention**

Advisory Board on Geriatrics (1990BPresent)

**American Federation for Clinical Research**

Councilor Southern Section 1983-1986

**Federation of American Societies for Experimental Biology (FASEB)**

Member Scientific Advisory Committee for project on The Impact of Antihypertensive Drugs  
1994-1996

**American Society for Pharmacology and Experimental Therapeutics**

Member Clinical Pharmacology Executive Committee 1995B

### **American Society for Clinical Pharmacology and Therapeutics**

Member Nominating Committee 1995B  
Member Executive Committee 1996B  
Vice Chairman, Program Committee 1996B1997  
Chairman, Program Committee 1997-1998

### **Merck Foundation**

Selection Committee for International Fellowships in Clinical Pharmacology:  
**Member**-1994-2000

Selection Committee for International Fellowships in Clinical Pharmacology:  
**Chairman**-1996-2000

### **American Federation for Aging Research**

Selection Committee for Fellowships in Clinical PharmacologyX1992BPresent

### **American Board of Clinical Pharmacology**

Member of Board 1996B  
Member of Credentials Committee 1996—  
**Chairman Credentials Committee 1999- present**

### **National Institute of General Medical Sciences**

Review Committee Member

### **Societies:**

Association of American Physicians  
Honorary Fellow, American Gynecological and Obstetrical Society (AGOS)  
Fellow, American College of Physicians  
American Society for Clinical Investigation  
American Federation for Clinical Research  
Southern Society for Clinical Investigation  
American Society for Pharmacology and Experimental Therapeutics  
American Society for Clinical Pharmacology and Therapeutics  
New York Academy of Sciences  
Fellow, American College of Clinical Pharmacology  
British Pharmacological Society

Fellow, Royal College of Physicians of London  
Fellow, Royal College of Physicians of Edinburgh  
Fellow, The American Heart Association Council for High Blood Pressure Research  
The American Heart Association Council for Basic Science  
The American Heart Association Council on the Circulation

### **Hospital**

Vanderbilt Hospital Medical BoardXMember Executive Committee (1989B1996)  
Vanderbilt Hospital Quality Review Committee (Chairman 1989B1996)  
Vanderbilt University Medical Center - Self-Insurance (malpractice) Trust Committee (1994B1996)  
Vanderbilt Institutional Review Board (Chairman 1983B1985)  
Committee on Toxic Hazards  
Search Committee for Chair of General Internal Medicine  
Conflict of Interest Committee

### **Medical Licensure**

Licensed to practice Medicine in the State of Tennessee (License .....)  
Registered with General Medical Council (United Kingdom)

### **Specialist Certification**

#### **(Internal Medicine)**

Member of the Royal College of Physicians (UK) (by examination)

#### **(Clinical Pharmacology)**

American Board of Clinical Pharmacology (By Examination)

#### **(Hypertension)**

American Society of Hypertension-Specialist in Hypertension

<b><u>Education:</u></b>	1950-1964	George Watson's Boys College, Edinburgh Dundee High School, Dundee
	1964B1970	St. Andrew's University/Dundee Medical School

### **University of St. Andrew's (1964B1970)**

**First Place in Class Certification:** Physics, Clinical Pathology, Social and Occupational Medicine

**Second Class Honours Certificates:** Chemistry, Biology and Physiology

**Degree Merits:** Physics, Chemistry, Social and Occupational Medicine

**Qualifications:** 1970 M.B., Ch.B., St. Andrew's University and Dundee Medical School

1974            Member of Royal College of Physicians (United Kingdom)

### **Previous Appointments:**

1970	House Surgeon, Bridge of Earn Hospital
1971	House Physician, Maryfield Hospital, Dundee (Professor Crooks)
1971B1972	World Health Organization, Research Fellow in Drug Monitoring, Dundee University
1972B1975	Registrar Department of Therapeutics, Dundee University
1975B1976	Lecturer in Therapeutics and Pharmacology, Dundee University and Senior Medical Registrar, Dundee Teaching Hospitals
1976B1978	Research Fellow in Clinical Pharmacology, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee
1978B1982	Assistant Professor of Medicine; Assistant Professor of Pharmacology, Vanderbilt University, Nashville, Tennessee
1982B1985	Associate Professor of Medicine, Associate Professor of Pharmacology, Vanderbilt University, Nashville, Tennessee
1999-2004	Assistant Vice Chancellor, Vanderbilt University, Nashville, Tennessee

### **Research Interests**

Molecular Genetics of Adrenergic Receptors  
Ethnic Differences in Drug Response  
Vascular Response  
Drug Metabolism and Disposition

### **Patents Held**

Antiviral Therapy Use of P-Glycoprotein Modulators: US Patent Application No. 09/370266.  
Antiviral Therapy Use of P-Glycoprotein Modulators: Thai Patent No. 059489.  
Antiviral Therapy Use of P-Glycoprotein Modulators; Nigerian Patent No. RP. 14,300.  
Antiviral Therapy Use of P-Glycoprotein Modulators; European Patent No. 1202737.

Method of Evaluating Immunosuppressive Regimens; U.S. Patent No. 6,329,153.



## **Original Investigations**

1. Wood AJJ Moir DC Campbell C Davidson JF Gallon SC Henney E McAllion S: Medicines evaluation and monitoring group: Central nervous system effects of pentazocine. British Medical Journal 1:305B307, 1974.
2. Brodlie P Henney C Wood AJJ: Problems of administering drugs by continuous infusion. British Medical Journal 1:383B385, 1974.
3. Moir DC Wood AJJ Davidson JF Gallon SC: Levodopa and positive direct antiglobulin tests. British Journal of Clinical Pharmacology 2:173, 1975.
4. Gerber JC McDonald JS Harbison RD Villeneuve JP Wood AJJ Nies AS: Effect of N-acetylcysteine on hepatic covalent binding of paracetamol (acetaminophen). Lancet 1:657-658, 1977.
5. O'Malley K Stevenson IH Ward CA Wood AJJ Crooks J: Determinants of anticoagulant control in patients receiving warfarin. British Journal of Clinical Pharmacology 4:309-314, 1977.
6. Kornhauser DM Wood AJJ Vestal RE Wilkinson GR Branch RA Shand DG: Biological determinants of propranolol disposition in man. Clinical Pharmacology and Therapeutics 23:165-174, 1978.
7. Wood AJJ Carr K Vestal RE Belcher S Wilkinson GR Shand DG: Direct measurement of propranolol bioavailability during accumulation to steady-state. British Journal of Clinical Pharmacology 6:345-350, 1978.
8. Wood AJJ Kornhauser DM Wilkinson GR Shand DG Branch RA: The influence of cirrhosis on steady state blood concentrations of unbound propranolol after oral administration. Clinical Pharmacokinetics 3:478-487, 1978.
9. Villeneuve JP Wood AJJ Shand DG Rogers L Branch RA: Impaired drug metabolism in experimental cirrhosis in the rat. Biochemical Pharmacology 27:2577-2581, 1978.
10. Wilkinson GR Wood AJJ Branch RA Shand DG: Intrinsic hepatic clearance in cirrhosis. Gastroenterology 75:347-348, 1978.
11. Vestal RE Wood AJJ Shand DG: Reduced beta-adrenoreceptor sensitivity in the elderly. Clinical Pharmacology and Therapeutics 26:181-186, 1979.
12. Wood AJJ Vestal RE Wilkinson GR Branch RA Shand DG: Effect of aging and cigarette smoking on antipyrine and indocyanine green elimination. Clinical Pharmacology and Therapeutics 26:16-20, 1979.

13. Vestal RE Wood AJJ Branch RA Shand DG Wilkinson GR: The effects of age and cigarette smoking on propranolol disposition. Clinical Pharmacology and Therapeutics 26:8-15, 1979.
14. Wood M Shand DG Wood AJJ: Altered drug binding due to the use of indwelling heparinized cannulas (heparin-lock) for sampling. Clinical Pharmacology and Therapeutics 25:103-107, 1979.
15. Wood M Shand DG Wood AJJ: Propranolol binding in plasma during cardiopulmonary bypass. Anesthesiology 51:512-516, 1979.
16. Wood AJJ Villeneuve JP Branch RA Rogers LW Shand DG: Intact hepatocyte theory of impaired drug metabolism in experimental cirrhosis in the rat. Gastroenterology 76:1358-1362, 1979.
17. Batchelor ED O'Day DM Shand DG Wood AJJ: Interaction of topical and oral timolol in glaucoma. Ophthalmology 86:60-65, 1979.
18. Wood M Wood AJJ: Reduction of catheter-associated sepsis in parenteral nutrition using heparin. (Letter). British Medical Journal 2:611-2, 1979.
19. Desmond PV Roberts RK Wood AJJ Dunn GD Wilkinson GR Schenker S: Effect of heparin administration on plasma binding of benzodiazepines. British Journal of Clinical Pharmacology 9:171-175, 1980.
20. Wood M Shand DG Wood AJJ: The sympathetic response to profound hypothermia and circulatory arrest in infants. Canadian Anaesthetists Society Journal 27:125-131, 1980.
21. Wood M Berman ML Harbison RD Hoyle P Phythyon JM Wood AJJ: Halothane-induced hepatic necrosis in triiodothyronine-pretreated rats. Anesthesiology 52:470-476, 1980.
22. Wood AJJ Robertson D Robertson RM Wilkinson GR Wood M: Elevated plasma free drug concentrations of propranolol and diazepam during cardiac catheterization. Circulation 62:1119-1122, 1980.
23. Wood AJJ Vestal RE Spannath CL Stone WJ Wilkinson GR Shand DG: Propranolol disposition in renal failure. British Journal of Clinical Pharmacology 10:561-566, 1980.
24. Wood M Wood AJJ: Changes in Plasma drug binding and alpha 1-acid glycoprotein in mother and newborn infant. Clinical Pharmacology and Therapeutics 29:522-526, 1981.
25. Fraser J Nadeau J Robertson D Wood AJJ: Regulation of human leukocyte beta receptors by endogenous catecholamines: Relationship of leukocyte beta-receptor density to the cardiac sensitivity to isoproterenol. Journal of Clinical Investigation 67:1777-1784, 1981.



26. Feely J Wilkinson GR Wood AJJ: Reduction of liver blood flow and propranolol metabolism by cimetidine. New England Journal of Medicine 304:692-695, 1981.
27. Leftwich RB Floro JF Neal RA Wood AJJ: Dinitrophenol poisoning: a diagnosis to consider in undiagnosed fever. Southern Medical Journal 75:182-184, 1982.
28. FitzGerald GA Robertson D Wood AJJ: Beta-adrenoreceptor down-regulation by dynamic exercise and upright posture in man. Transactions of the Association of American Physicians 94:310-313, 1981.
29. Feely J Wilkinson GR McAllister CB Wood AJJ: Increased toxicity and reduced clearance of lidocaine by cimetidine. Annals of Internal Medicine 96:592-594, 1982.
30. Feely J Wood AJJ: Effects of cimetidine on the elimination and actions of ethanol in man. Journal of the American Medical Association 247:2819-2821, 1982.
31. Robertson RM Wood AJJ Vaughn WK Robertson D: Exacerbation of vasotonic angina pectoris by propranolol. Circulation 65:281-285, 1982.
32. Feely J Robertson D Island DP Wood AJJ: Cimetidine alters plasma catecholamine levels and cortisol and aldosterone excretion. The New England Journal of Medicine 306:1054, 1982.
33. Duff HJ Roden DM Brorson L Wood AJJ Dawson AK Primm RK Oates JA Smith RF Woosley RL: Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. Journal of American College of Cardiology 2:1134-1140, 1983.
34. Wood M Stone WJ Wood AJJ: Plasma binding of pancuronium: Effects of age, sex and disease. Anesthesia and Analgesia 62:29-32, 1983.
35. Feely J Wood AJJ: Effect of inhibitors of prostaglandin synthesis on hepatic drug clearance. British Journal of Clinical Pharmacology 15:109-111, 1983.
36. Feely J Nadeau J Wood AJJ: Effects of feeding on the systemic clearance of indocyanine green and propranolol blood concentrations and plasma binding. British Journal of Clinical Pharmacology 15:383-385, 1983.
37. Wells PG Feely J Wilkinson GR Wood AJJ: Effect of thyrotoxicosis on liver blood flow and propranolol disposition after long-term dosing. Clinical Pharmacology and Therapeutics 33:603-608, 1983.
38. Feely J Wood AJJ: Effect on apparent liver blood flow of histamine-receptor blockers and inhibition of prostaglandin synthesis. Clinical Pharmacology and Therapeutics 33:91-94, 1983.

39. Feldman RD Limbird LE Nadeau J FitzGerald GA Robertson D Wood AJJ: Dynamic regulation of leukocyte beta adrenergic receptor agonist interactions by physiological changes in circulating catecholamines. Journal of Clinical Investigation 72:164-170, 1983.
40. Uetrecht J Wood AJJ Phythyon JM Wood M: Contrasting effects on halothane hepatotoxicity in the phenobarbital-hypoxia and triiodothyronine model: Mechanistic implications. Anesthesiology 59:196-201, 1983.
41. Herman RJ Nakamura K Wilkinson GR Wood AJJ: Induction of propranolol metabolism by rifampicin. British Journal of Clinical Pharmacology 16:565-569, 1983.
42. Feldman RD Limbird LE Nadeau J Robertson D Wood AJJ: Leukocyte  $\beta$ -receptor alterations in hypertensive subjects. Journal of Clinical Investigation 73:648-653, 1984.
43. Riddell JG McAllister CB Wilkinson GR Wood AJJ Roden DM: A new method for constant plasma drug concentrations: application to lidocaine. Annals of Internal Medicine 100:25-28, 1984.
44. Dawson AK Reece SB Wood AJJ Duff H Woosley RL Smith RF: Electrophysiological effects of high-dose propranolol in dogs: Evidence *in vivo* for effects not mediated by the  $\beta$ -adrenoreceptor. Journal of Pharmacology and Experimental Therapeutics 229:91-97, 1984.
45. Hammon JW Jr Wood AJJ Prager RL Wood M Muirhead J Bender HW Jr: Perioperative beta blockade with propranolol: Reduction in myocardial oxygen demands and the incidence of atrial and ventricular arrhythmias. Annals of Thoracic Surgery 38:363-367, 1984.
46. Feldman RD Limbird LE Nadeau J Robertson D Wood AJJ: Alterations in leukocyte  $\beta$ -receptor affinity with aging: An explanation for altered beta adrenergic sensitivity in the elderly. The New England Journal of Medicine 310:815-819, 1984.
47. Wood M Wood AJJ: Contrasting effects of halothane, isoflurane and enflurane on *in vivo* drug metabolism in the rat. Anesthesia and Analgesia 63:709-714, 1984.
48. Raghuram TC Koshakji RP Wilkinson GR Wood AJJ: Polymorphic ability to metabolize propranolol in man alters 4-hydroxy propranolol levels but not beta blockade. Clinical Pharmacology and Therapeutics 36:51-56, 1984.
49. Wang T Roden DM Wolfenden HT Woosley RL Wood AJJ Wilkinson GR: Influence of Genetic Polymorphism on the metabolism and disposition of encainide in man. Journal of Pharmacology and Experimental Therapeutics 228:605-611, 1984.
50. Reilly CS Wood AJJ Wood M: Variability of fentanyl kinetics in man: Computer predicted plasma concentrations for three intravenous dosage regimens. Anaesthesia 40:837-843, 1985.

51. Reilly CS Wood M Koshakji RP Wood AJJ: Ultra-short-acting beta-blockade: a comparison with conventional beta-blockade. Clinical Pharmacology and Therapeutics 38:579-585, 1985.
52. Wright JT Jr Goodman RP Gorwit J Flamenbaum W Mroczek W Reeves RL Carr AA Prisant LM Wood AJJ Nadeau J Calderone P Jogklekar S Lenzi R: Combined labetalol and hydrochlorothiazide therapy in hypertension. Clinical Pharmacology and Therapeutics 38:24-27, 1985.
53. Reilly CS Wood AJJ Koshakji RP Wood M: The effect of halothane on drug disposition: Contribution of changes in intrinsic drug metabolizing capacity and hepatic blood flow. Anesthesiology 63:70-76, 1985.
54. Biollaz J Shaheen O Wood AJJ: Cimetidine inhibition of ethmozine metabolism. Clinical Pharmacology and Therapeutics 37:665-668, 1985.
55. Koshakji RP Wood AJJ: A modified, sensitive HPLC method for measurement of propranolol with fluorescence detection. Journal of Pharmaceutical Sciences 75:87-89, 1986.
56. Wood M Uetrecht J Phythyon JM Shay S Sweetman BJ Shaheen O Wood AJJ: The effect of cimetidine on anesthetic metabolism and toxicity. Anesthesia and Analgesia 65:481-488, 1986.
57. Bergstrand RH Wang T Roden DM Stone WJ Wolfenden HT Woosley RL Wilkinson GR Wood AJJ: Encainide disposition in patients with renal failure. Clinical Pharmacology and Therapeutics 40:64-70, 1986.
58. Bergstrand RH Wang T Roden DM Avant GR Sutton WW Siddoway LA Wolfenden H Woosley RL Wilkinson GR Wood AJJ: Encainide disposition in patients with chronic cirrhosis. Clinical Pharmacology and Therapeutics 40:148-154, 1986.
59. Reilly CS Biollaz J Koshakji RP Wood AJJ: Enprostil, in contrast to cimetidine, does not inhibit propranolol metabolism. Clinical Pharmacology and Therapeutics 40:37-41, 1986.
60. Shaheen O Patel J Avant GR Hamilton M Wood AJJ: Effect of cirrhosis and debrisoquine phenotype on the disposition and effects of pinacidil. Clinical Pharmacology and Therapeutics 40:650-655, 1986.
61. Gordon L Wood AJJ Koshakji RP Wilkinson GR Dupont WD Wood M: Acute effects of halothane anesthesia on arterial and venous concentrations of propranolol in the dog. Anesthesiology 67:225-230, 1987.
62. Jones LG Gray ME Wood AJJ LeQuire VS: Beta-adrenergic receptor properties of pulmonary alveolar type II cell preparation from the adult rat. Lung 165:201-211, 1987.

63. Wood M Hyman S Wood AJJ: A clinical study of sensitivity to sodium nitroprusside during controlled hypotensive anesthesia in young and elderly patients. Anesthesia and Analgesia 66:132-136, 1987.
64. Koshakji RP Wood AJJ: Improved high-performance liquid chromatographic method for the simultaneous determination of propranolol and 4-hydroxypropranolol in plasma with fluorescence detection. Journal of Chromatography 422:294-300, 1987.
65. Reilly CS Merrell J Wood AJJ Koshakji RP Wood M: Comparison of the effects of isoflurane or fentanyl-nitrous oxide anaesthesia on propranolol disposition in dogs. British Journal of Anaesthesia 60:791-796, 1988.
66. Naslund TC Merrell WJ Nadeau JH Wood AJJ:  $\alpha$ -adrenergic blockade makes minimal contribution to ketanserin's hypotensive effect. Clinical Pharmacology and Therapeutics 44:699-703 1988.
67. Whelan E Wood AJJ Koshakji RP Shay S Wood M: Halothane inhibition of propranolol metabolism is stereoselective. Anesthesiology 71:561-564, 1989.
68. Prakash C Koshakji RP Wood AJJ Blair IA: Simultaneous determination of propranolol enantiomers in plasma by high performance liquid chromatography with fluorescence detection. Journal of Pharmacological Sciences 78:771-775, 1989.
69. Zhou HH Silberstein DJ Koshakji RP Wood AJJ: Interindividual differences in beta-receptor density contribute to variability in response to beta-adrenoreceptor antagonists. Clinical Pharmacology and Therapeutics 45:587-592, 1989.
70. Anthony L Koshakji RP Wood AJJ: Multiple pathways of propranolol's metabolism are inhibited by debrisoquine. Clinical Pharmacology and Therapeutics 46:297-300, 1989.
71. Bullington J Perry SM Rigby J Pinkerton M Rogers D Lewis TC Preganz P Wood AJJ Wood M: The effect of advancing age on the sympathetic response to laryngoscopy and endotracheal intubation. Anesthesia and Analgesia 68:603-608, 1989.
72. Silberstein DJ Rigby J Merrell T Naslund T Wood AJJ: Altered  $\beta$ -adrenoceptor internalization does not explain reduced  $\beta$ -adrenergic responsiveness in the elderly. Journal of Clinical Endocrinology and Metabolism 68:131-134, 1989.
73. Zhou HH Koshakji RP Silberstein DJ Wilkinson GR Wood AJJ: Racial Differences in Drug Response: Altered sensitivity to and clearance of propranolol in men of Chinese descent as compared with American whites. New England Journal of Medicine 320:565-570, 1989.
74. Kroemer HK Funck-Brentano C Silberstein DJ Wood AJJ Eichelbaum M Woosley RL Roden DM: Stereoselective disposition and pharmacological activity of propafenone enantiomers. Circulation 79:1068-1076, 1989.

75. Whelan E Wood AJJ Shay S Wood M: Lack of effect of spinal anesthesia on drug metabolism. Anesthesia and Analgesia 69:307-312, 1989.
76. Shaheen O Biollaz J Koshakji RP Wilkinson GR Wood AJJ: Influence of debrisoquine phenotype on the inducibility of propranolol metabolism. Clinical Pharmacology and Therapeutics 45:439-443, 1989.
77. Rigby JW Wood AJJ: Use of N-ethylmaleimide to directly determine the proportion of beta-adrenergic receptors exhibiting high affinity for agonists on human mononuclear leukocyte membranes. Biochemical Pharmacology 38:2755-2761, 1989.
78. Naslund T Silberstein DJ Merrell WJ Nadeau JH Wood AJJ: Low sodium intake corrects abnormality in beta-receptor-mediated arterial vasodilation in patients with hypertension: correlation with beta-receptor function *in vitro*. Clinical Pharmacology and Therapeutics 48:87-95, 1990.
79. Merrell WJ Gordon L Wood AJJ Shay S Jackson EK Wood M: The effect of halothane on morphine disposition: relative contributions of the liver and kidney to morphine glucuronidation in the dog. Anesthesiology 72:308-314, 1990.
80. Murray KT Reilly C Koshakji RP Roden DM Lineberry MD Wood AJJ Siddoway LA Barbey JT Woosley RL: Suppression of ventricular arrhythmias in man by dextro-propranolol independent of beta-adrenergic receptor blockade. Journal of Clinical Investigation 85:836-842, 1990.
81. Lee JT Kroemer HK Silberstein DJ Funck-Brentano C Lineberry MD Wood AJJ Roden DM Woosley RL: The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. The New England Journal of Medicine 322:1764-1768, 1990.
82. Zhou HH Anthony LB Roden DM Wood AJJ: Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clinical Pharmacology and Therapeutics 47:686-693, 1990.
83. Zhou HH Wood AJJ: Differences in stereoselective disposition of propranolol do not explain sensitivity differences between white and Chinese subjects: correlation between the clearance of (-)- and (+)-propranolol. Clinical Pharmacology and Therapeutics 47:719-723 1990.
84. Funck-Bretano C Silberstein DJ Roden DM Wood AJJ Woosley RL: A mechanism of D-(+)-sotalol effects on heart rate not related to  $\beta$ -adrenoreceptor antagonism. British Journal of Clinical Pharmacology 30:195-202 1990.
85. Zhou HH Anthony LB Wood AJJ Wilkinson GR: Induction of polymorphic 4'-hydroxylation of S-mephenytoin by rifampicin. British Journal of Clinical Pharmacology 30:471-475, 1990.

86. Robin DW Hasan SS Lichtenstein MJ Shiavi RG Wood AJJ: Dose related effect of triazolam on postural sway. Clinical Pharmacology and Therapeutics 49:581-588, 1991.
87. Perry SM Whelan E Shay S Wood AJJ Wood M: Effect of I.V. Anaesthesia with propofol on drug distribution and metabolism in the dog. British Journal of Anaesthesia 66:66-72, 1991.
88. Zhou HH Wood AJJ: Increased suppression of exercise-induced Increase in renin by propranolol in Chinese subjects. Clinical Pharmacology and Therapeutics 50:150-156, 1991.
89. Deegan R He HB Wood AJJ Wood M: Effects of anesthesia on norepinephrine kinetics. Comparison of propofol and halothane anesthesia in dogs. Anesthesiology 75:481-488, 1991.
90. Bluhm RE Bobbitt RG Welch LW Wood AJJ Bonfiglio JF Sarzen C Heath AJ Branch RA: Elemental mercury vapour toxicity treatment, and prognosis after acute, intensive exposure in chloralkali plant workers. Part 1: History, neuropsychological findings and chelator effects. Human and Experimental Toxicology 11:201-210, 1992.
91. Bluhm RE Breyer JA Bobbitt RG Welch LW Wood AJJ Branch RA: Elemental mercury vapor toxicity, treatment, and prognosis after acute, intensive exposure in chloralkali plant workers. Part II. Hyperchloraemia and genitourinary symptoms. Human and Experimental Toxicology 11:211-215, 1992.
92. Zhou HH Whelan E Wood AJJ: Lack of effect of aging on the stereochemical disposition of propranolol. British Journal of Clinical Pharmacology 33:121-123, 1992.
93. Edeki T Robin DW Prakash C Blair I Wood AJJ: Sensitive assay for triazolam in plasma following low oral doses. Journal of Chromatography 577:190-194, 1992.
94. Yun CH Wood M Wood AJJ Guengerich FP: Identification of the Pharmacogenetic Determinants of Alfentanil Metabolism: Cytochrome P-450 3A4. An explanation of the Variable Elimination Clearance. Anesthesiology 77:467-474, 1992.
95. He HB Deegan RJ Wood M Wood AJJ: Optimization of high-performance liquid chromatographic assay for catecholamines. Determination of optimal mobile phase composition and elimination of species-dependent differences in extraction recovery of 3,4-dihydroxybenzylamine. Journal of Chromatography 574:213-218, 1992.
96. Zhou HH Adedoyin A Wood AJJ: Differing effect of atropine on heart rate in Chinese and white subjects. Clinical Pharmacology and Therapeutics 52:120-124, 1992.
97. Kinirons MT O'Shea D Downing TE Fitzwilliam AT Joellenbeck L Groopman JD Wilkinson GR Wood AJJ: Absence of correlations among three putative *in vivo* probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics 54:621-629, 1993.

98. Deegan R He HB Wood AJJ Wood M: Effect of enflurane and isoflurane on norepinephrine kinetics: a new approach to assessment of sympathetic function during anesthesia. Anesthesia and Analgesia 77:49-54, 1993.
99. Stein M Deegan R He HB Wood AJJ: Beta adrenergic receptor-mediated release of norepinephrine in the human forearm. Clinical Pharmacology and Therapeutics 54:58-64, 1993.
100. Robin DW Hasan SS Lichtenstein MJ Shiavi RG Wood AJJ: Dose-related effect of triazolam on postural sway. Clinical Pharmacology Therapeutics 54:229-230, 1993.
101. Stein MS Deegan R Wood AJJ: Long term exposure to beta<sub>2</sub> receptor agonist specifically desensitizes beta-receptor-mediated venodilation. Clinical Pharmacology and Therapeutics 54:187-193, 1993.
102. Robin DW Lee MH Hasan SS Wood AJJ: Triazolam in cirrhosis: Pharmacokinetics and Pharmacodynamics. Clinical Pharmacology and Therapeutics 54:630-637, 1993.
103. Zhou HH Sheller JR He N Wood M Wood AJJ: Ethnic differences in response to morphine. Clinical Pharmacology and Therapeutics 54:507-513, 1993.
104. Zhou H Shay SD Wood AJJ: Contribution of differences in plasma binding of propranolol to ethnic differences in sensitivityXcomparison between Chinese and Caucasians. Chinese Medical Journal 106:898-902, 1993.
105. He H Edeki T Wood AJJ: Determination of low plasma timolol concentrations following topical application of timolol eye drops in humans by HPLC with electrochemical detection. Journal of Chromatography, B 661:351-356, 1994.
106. Krivoruk Y Kinirons MT Wood AJJ Wood M: Metabolism of cytochrome P4503A substrates in vivo administered by the same route: Lack of correlation between alfentanil clearance and erythromycin breath test. Clinical Pharmacology and Therapeutics 56:608-614, 1994.
107. Deegan R Wood AJJ:  $\beta$ -Receptor antagonism does not fully explain esmolol-induced hypotension. Clinical Pharmacology and Therapeutics 56:223-228, 1994.
108. Stein CM Nelson R Brown M Wood M Wood AJJ: Dietary sodium intake modulates vasodilation mediated by nitroprusside but not by methacholine in the human forearm. Hypertension 25:1220-1223, 1995.
109. Zhou HH Wood AJJ: Stereoselective disposition of carvedilol is determined by CYP2D6. Clinical Pharmacology and Therapeutics 57:518-524, 1995.
110. Lang CC Stein CM Brown RM Deegan R Nelson R He HB Wood M Wood AJJ: Attenuation of isoproterenol-mediated vasodilation in blacks. New England Journal of Medicine 333:155-160, 1995.

111. Stein CM Nelson R Deegan R He H Wood M Wood AJJ: Forearm beta adrenergic receptor-mediated vasodilation is impaired, without alteration of forearm norepinephrine spillover, in borderline hypertension. Journal of Clinical Investigation 96:579-585, 1995.
112. Deegan R He HB Krivoruk Y Wood AJJ Wood M: Regulation of norepinephrine release by  $\beta$ 2-adrenergic receptors during halothane anesthesia. Anesthesiology 82:1417-1425, 1995.
113. Caraco Y Tateishi T Wood AJJ: Interethnic difference in omeprazole's inhibition of diazepam metabolism. Clinical Pharmacology and Therapeutics 58:62-72, 1995.
114. Stein CM Nelson R Deegan R He H Inagami T Frazer M Badr KF Wood M Wood AJJ: Tachyphylaxis of human forearm vascular responses does not occur rapidly after exposure to isoproterenol. Hypertension 25:1294-1300, 1995.
115. Tateishi T Wood AJJ Guengerich FP Wood M: Biotransformation of tritiated fentanyl in human liver microsomes. Monitoring metabolism using phenylacetic acid and 2-phenylethanol. Biochemical Pharmacology 50:1921-1924, 1995.
116. Tateishi T Krivoruk Y Ueng YF Wood AJJ Guengerich FP Wood M: Identification of human liver cytochrome P450 3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesthesia and Analgesia 82:167-72, 1996.
117. Stein CM Nelson R Brown M He H Wood M Wood AJJ: Dietary sodium intake modulates systemic but not forearm norepinephrine release. Clinical Pharmacology and Therapeutics 58:425-433, 1995.
118. Tateishi T Graham SG Krivoruk Y Wood AJJ: Omeprazole does not affect measured CYP 3A4 activity using the erythromycin breath test. British Journal of Clinical Pharmacology 40:411-412, 1995.
119. Stein CM He H Pincus T Wood AJJ: Cyclosporine impairs vasodilation without increased sympathetic activity in humans. Hypertension 26:705-710, 1995.
120. Edeki TI He H Wood AJJ: Pharmacogenetic explanation for excessive  $\beta$ -blockade following timolol eye drops: potential for oral-ophthalmic drug interaction. Journal of the American Medical Association 274:1611-1613, 1995.
121. Robin DW Hasan SS Edeki T Lichtenstein MJ Shiavi RG Wood AJJ: Increased baseline sway contributes to increased losses of balance in older people following triazolam. Journal of the American Geriatrics Society 44:300-304, 1996.
122. Lang CC Brown RM Kinirons MT Deathridge MA Guengerich FP Kelleher D O'Briain DS Ghishan FK Wood AJJ: Decreased intestinal CYP3A in celiac disease: reversal after successful gluten-free diet: a potential source of interindividual variability in first-pass drug metabolism. Clinical Pharmacology and Therapeutics 59:41-6, 1996.



123. Lang CC Stein CM He HB Wood AJJ: Angiotensin-converting enzyme inhibition and sympathetic activity in healthy subjects. Clinical Pharmacology and Therapeutics 59:668-74 1996.
124. Caraco Y Sheller J Wood AJJ: Pharmacogenetic determination of the effects of codeine and prediction of drug interactions. Journal of Pharmacology and Experimental Therapeutics 278: 1165-1174, 1996.
125. Stein CM Nelson RA He HB Wood M Wood AJJ: Norepinephrine Release in the Human Forearm: Effects of Epinephrine. Hypertension 30:1078-1084, 1997.
126. Kinirons MT Lang CC He HB Ghebreselasie K Shay S Robin DW Wood AJJ: Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Southern Asians: ethnicity and CYP3A activity. British Journal Clinical Pharmacology 41:69-72, 1996.
127. Stein CM Kinirons MT Pincus T Wilkinson GR Wood AJJ: Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine. Clinical Pharmacology and Therapeutics 59:47-51, 1996.
128. Caraco Y Tateishi T Guengerich FP Wood AJJ: Microsomal codeine N-demethylation: Co-segregation with cytochrome P450A4 activity. Drug Metabolism and Disposition 24:761-764, 1996.
129. Caraco Y Lagerstrom PO Wood AJJ: Ethnic and Genetic Determinants of Omeprazole Disposition and Effect. Clinical Pharmacology and Therapeutics 60:157-167, 1996.
130. Caraco Y Wilkinson GR Wood AJJ: Differences between White Subjects and Chinese Subjects in the In Vivo Inhibition of Cytochrome P450s 2C19, 2D6, and 3A by Omeprazole. Clinical Pharmacology and Therapeutics 60:396-404, 1996.
131. Lang CC Stein CM He HB Belas FJ Blair IA Wood M Wood AJJ: Blunted blood pressure response to central sympathoinhibition in normotensive blacks: Increased importance of non-sympathetic factors in blood pressure maintenance in blacks. Hypertension 30:157-162, 1997.
132. Lang CC Rayos GH Chomsky DB Wood AJJ Wilson JR: Effect of sympathoinhibition on exercise performance in patients with heart failure. Circulation 96:238-45, 1997.
133. Stein CM Wood AJJ Pincus T: Implementation of Multiple Outpatient Formularies - Undesirable Effects. Clinical Pharmacology and Therapeutics 61:1-7, 1997.
134. Caraco Y Sheller J Wood AJJ: Pharmacogenetic determinants of codeine induction by rifampin: The impact on codeine's respiratory, psychomotor and miotic effects. Journal of Pharmacology and Experimental Therapeutics 281: 330-336, 1997.

135. Stein CM Deegan R Wood AJJ: Lack of correlation between arterial and venous  $\beta$ -adrenergic receptor sensitivity. Hypertension 29:1273-1277, 1997.
136. Stein CM Lang CC Nelson R Brown M Wood AJJ: Vasodilation in black Americans: Attenuated nitric oxide-mediated responses. Clinical Pharmacology and Therapeutics 62:436-443, 1997.
137. Lang CC Stein CM Nelson RA He HB Belas FJ Blair IA Wood M Wood AJJ: Sympathoinhibitory response to Clonidine is blunted in patients with heart failure. Hypertension 30:392-397, 1997.
138. Stein CM Brown N Carlson MG Campbell P Wood AJJ: Co-administration of glyburide and minoxidil, drugs with opposing effects on potassium channels. Clinical Pharmacology and Therapeutics 61:662-668, 1997.
139. He H Stein CM Christman B Wood AJJ: Determination of catecholamines in sheep plasma by high-performance liquid chromatography with electrochemical detection: comparison of deoxyepinephrine and 3,4-dihydroxybenzylamine as internal standard. Journal of Chromatography, B 701:115-119, 1997.
140. Tateishi T Soucek P Caraco Y Guengerich FP Wood AJJ: Colchicine biotransformation by human liver microsomes. Identification of CYP3A4 as the major isoform responsible for colchicine demethylation. Biochemical Pharmacology 53:111-6, 1997.
141. He H Shay S Caraco Y Wood M Wood AJJ: Simultaneous Determination of Codeine and Its Seven Metabolites in Plasma and Urine by High-Performance Liquid Chromatography with Ultraviolet and Electrochemical Detection. Journal of Chromatography, B 708:185-193, 1998.
142. Wandel C Lang CC Cowart DC Girard AF Bramer S Flockhart DA Wood AJJ: Effect of CYP3A inhibition on vesnarinone metabolism in humans. Clinical Pharmacology and Therapeutics 63:506-511, 1998.
143. Kim RB Fromm MF Wandel C Leake B Wood AJJ Roden DM Wilkinson GR: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. The Journal of Clinical Investigation, 101:289-294, 1998.
144. Choy AM Lang CC Roden DM Robertson D Wood AJJ Robertson RM Biaggioni I: Abnormalities of the QT interval in primary disorders of autonomic failure. American Heart Journal 136:664-671, 1998.
145. Stein CM He HB Wood AJJ: Basal and stimulated sympathetic responses after epinephrine: No evidence of augmented responses. Hypertension 32:1016-1021, 1998.

146. Robbins IM Cuiper LL Stein CM Wood AJJ He HB Parker R Christman BW: Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheep. Journal of Applied Physiology 85:731-737, 1998.
147. Stein CM Brown N Vaughan DE Lang CC Wood AJJ: Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. Journal of the American College of Cardiology, 32:117-122, 1998.
148. Kim RB Wandel C Leake B Cvetkovic M Fromm MF Dempsey PJ Roden MM Belas F Chaudhary AK Roden DM Wood AJJ Wilkinson GR: Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. Pharmaceutical Research 16:408-414, 1999.
149. Stein CM Murray JJ Wood AJJ: Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clinical Chemistry 45:1477-1484, 1999.
150. Caraco Y Sheller J Wood AJJ: Impact of ethnic origin and quinidine coadministration on codeine=s disposition and pharmacodynamic effects. Journal of Pharmacology and Experimental Therapeutics 290:413-422, 1999.
151. Xie HG Kim RB Stein CM Wilkinson GR Wood AJJ: Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. British Journal of Clinical Pharmacology 48: 402-408, 1999.
152. Xie HG Stein CM Kim RB Xiao ZS He N Zhou HH Gainer JV Brown NJ Haines JL Wood AJJ: Frequency of functionally important beta-2 adrenoceptor polymorphisms varies markedly among African-American, Caucasian and Chinese individuals. Pharmacogenetics 9:511-516, 1999.
153. Kinirons MT Krivoruk Y Wilkinson GR Wood AJJ: Effects of ketoconazole on the erythromycin breath test and the dapsone recovery ratio. British Journal of Clinical Pharmacology 47:223-225, 1999.
154. Xie HG Stein CM Kim RB Wilkinson GR Flockhart DA Wood AJJ: Allelic, genotypic and phenotypic distributions of S-mephenytoin 4'-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 9:539-549, 1999.
155. Xie HG Kim RB Stein CM Gainer JV Brown NJ Wood AJJ:  $\alpha$ 1A Adrenergic receptor polymorphism: associated with ethnicity but not hypertension. Pharmacogenetics 9:651-656, 1999.
156. Wandel C Kim RB Kajiji S Guengerich FP Wilkinson GR Wood AJJ: P-glycoprotein and cytochrome P450 3A inhibition: Dissociation of inhibitory potencies. Cancer Research 59:3944-3948, 1999.

157. Kinirons MT O'Shea D Kim RB Groopman JD Thummel KE Wilkinson GR Wood AJJ: Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clinical Pharmacology and Therapeutics 66:224-31, 1999.
158. Xie HG Stein CM Kim RB Gainer JV Sofowora G Dishy V Brown NJ Goree RE Haines JL Wood AJJ: Human beta-2 adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. Clinical Pharmacology and Therapeutics 67:670-675, 2000.
159. He H Sadeque A Erve JCL Wood AJJ Hachey DL: Quantitation of loperamide and N-demethyl-loperamide in human plasma using electrospray ionization with selected reaction ion monitoring LC/MS. Journal of Chromatography, B 744:323-331, 2000.
160. Wandel C Kim RB Guengerich FP Wood AJJ: Mibefradil is a P-glycoprotein substrate and a potent inhibitor of both P-glycoprotein and CYP3A *in vitro*. Drug Metabolism and Disposition 28:895-8, 2000.
161. Sadeque A Wandel C He H Shah S Wood AJJ: Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics 68:231-7, 2000.
162. Wandel C Witte JS Hall JM Stein CM Wood AJJ Wilkinson GR: CYP3A activity in African-American and European-American men: population differences and functional effect of the CYP3A4\*1B 5'-promoter region polymorphism. Clinical Pharmacology and Therapeutics 68:82-91, 2000.
163. Choo EF Leake B Wandel C Imamura H Wood AJJ Wilkinson GR Kim RB: Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes. Drug Metabolism and Disposition 28:655-660, 2000.
164. Stein CM Lang CC Singh I He HB Wood AJJ: Increased vascular adrenergic vasoconstriction and decreased vasodilation in Blacks: Additive mechanisms leading to enhanced vascular reactivity. Hypertension 36:945-951, 2000.
165. Xie HG Dishy V Sofowora G Kim RB Landau R Smiley RM Zhou HH Wood AJJ Harris P Stein CM: Arg<sub>389</sub>Gly  $\beta_1$ -adrenoceptor polymorphism varies in frequency among different ethnic groups but does not alter response *in vivo*. Pharmacogenetics 11:191-197, 2001.
166. Stein CM Sadeque AJ Murray JJ Wandel C Kim RB Wood AJJ: Cyclosporine pharmacokinetics and pharmacodynamics in African American and white subjects. Clinical Pharmacology and Therapeutics 69:317-323, 2001.
167. Dickmann LJ Rettie AE Kneller MB Kim RB Wood AJJ Stein CM Wilkinson GR Schwarz UI: Identification and functional characterization of a new CYP2C9 variant (CYP2C9\*5<sup>1</sup>) expressed among African Americans. Molecular Pharmacology 60:382-387, 2001.

168. Caraco Y Muszkat M Wood AJJ: Phenytoin metabolic ratio: a putative marker of CYP2C9 activity *in vivo*. Pharmacogenetics 11:587-596, 2001.
169. Sofowora G Dishy V Xie HG Imamura H Nishimi Y Morales CR Morrow JD Kim RB Stein CM Wood AJJ: *In vivo* effects of Glu298Asp endothelial nitric oxide synthase. Pharmacogenetics 11:809-814, 2001.
170. Dishy V Sofowora G Harris PA Kandcer M Zhan F Wood AJJ Stein CM: The Effect of sildenafil on nitric oxide-mediated vasodilation in healthy men. Clinical Pharmacology and Therapeutics 70:270-279, 2001.
171. Dishy V Sofowora GG Xie HG Kim RB Byrne D Stein CM Wood AJJ: The effect of common polymorphisms of the beta-2 adrenergic receptor on agonist-mediated vascular desensitization. New England Journal of Medicine 345:1030-1035, 2001.
172. Landau R Wood AJJ Emala CW Kim RB Xie HG Dishy V Stein CM Smiley RM: Beta2-adrenergic receptor genotype and preterm delivery. American Journal of Obstetrics and Gynecology 187:1294-1298, 2002.
173. Wandel C Kim RB Wood M Wood AJJ: The interaction of morphine, fentanyl, sufentanil, alfentanil and loperamide with the efflux drug transporter P-glycoprotein. Anesthesiology 96:913-920, 2002.
174. Landau R Dishy D Wood AJJ Stein CM Smiley RM: Disproportionate decrease in alpha-compared with beta-adrenergic sensitivity in the dorsal hand vein in pregnancy favors vasodilation. Circulation 106:1116-1120, 2002.
175. Sofowora GG Dishy V Muszkat M Xie HG Kim RB Harris PA Prasad H Byrne DW Nair UB Wood AJJ Stein CM: A common beta1-adrenergic receptor polymorphism (Arg389Gly) affects blood pressure response to beta-blockade. Clinical Pharmacology and Therapeutics 73:366-371, 2003.
176. Dishy V Gupta S Landau R Xie HG Kim RB Smiley RM Byrne DW Wood AJJ Stein CM: G-protein Beta-3 subunit 825 C/T polymorphism is associated with weight gain during pregnancy. Pharmacogenetics 13:241-242, 2003.
177. Haas DW Wilkinson GR Kuritzkes DR Richman DD Nicotera J Mahon LF Sutcliffe C Siminski S Andersen J Coughlin K Clayton EW Haines J Marshak A Saag M Lawrence J Gustavson J Bennett JA Christensen R Matula MA Wood AJJ for the Adult AIDS Clinical Trials Group: A Multi-Investigator/Institutional DNA Bank for AIDS-Related Human Genetic Studies: AACTG Protocol A5128. HIV Clinical Trials 4:287-300, 2003.
178. Dishy V Sofowora G Imamura H Nishimi Y Xie HG Wood AJJ Stein CM: Nitric oxide production decreases after salt loading but is not related to blood pressure changes or nitric oxide-mediated vascular responses. Journal of Hypertension 21:153-157, 2003.

179. Muszkat M Sofowora GG Wood AJ Stein CM: Alpha2-adrenergic receptor-induced vascular constriction in Blacks and Whites. Hypertension 43:31-35, 2004.
180. Dishy V Harris PA Pierce R Prasad HC Sofowora G Bonar HL Wood AJJ Stein CM: Sildenafil does not improve nitric oxide-mediated endothelium-dependent vascular responses in smokers. British Journal of Clinical Pharmacology 57:209-212, 2004.
181. Landau R Xie HG Dishy V Wood AJJ Stein CM Smiley RM: No association of the Asp298 variant of the endothelial nitric oxide synthase gene with pre-eclampsia. American Journal of Hypertension 17:391-394, 2004.
182. Dishy V Landau R Sofowora GG Xie HG Smiley RM Kim RB Byrne DW Wood AJJ Stein CM: Beta2-adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity *in vivo*. Pharmacogenetics 14:517-522, 2004.
183. Sofowora GG Dishy V Landau R Xie HG Prasad HC Byrne DW Smiley RM Kim RB Wood AJJ Stein CM: Alpha-<sub>1A</sub> adrenergic receptor polymorphism and vascular response. Clinical Pharmacology and Therapeutics 75:539-45, 2004.
184. ....  
..... (In press,.....).
185. ....  
..... (Submitted, ....).
186. ....  
..... (Submitted,.....).
187. ....  
..... (Submitted, ....).
188. ....  
..... (Submitted, ....).

## **Textbooks**

**Wood M Wood AJJ: Drugs and Anesthesia: Pharmacology for Anesthetists, Williams and Wilkins, Baltimore; 1st Edition (1982) 2nd Edition (1990).**

Chapter 1 Drug Disposition and Pharmacokinetics, Wood, AJJ.

Chapter 2 Drug Metabolism, Wood, AJJ.

Chapter 3 Drug Receptor Interactions, Wood, AJJ.

Chapter 4 Drug Interactions and Adverse Drug Reactions, Wood, AJJ.

Chapter 14 Adrenoreceptor Blocking Agents, Wood, AJJ.

Chapter 15 Hypotensive and Vasodilator Drugs, Wood, AJJ.

Chapter 22 Drugs and the Coagulation System, Wood, AJJ.

## **Book Chapters and Reviews**

1. Wood AJJ Crooks J: The effect of drugs on thyroid function tests. Prescriber's Journal 13:94-99, 1973.
2. Wood AJJ: "Medicine" self assessment questions (1975-76).
3. Wood AJJ: Continuous drug infusions: problems, solutions. Drug Therapy 2:14-21, 1977.
4. Wood AJJ Shand DG: Propranolol in the treatment of cardiovascular disease. Southern Medical Journal 71:591-594, 1978.
5. Shand DG Wood AJJ Vestal RE Wilkinson GR Branch RA: Pharmacokinetic and pharmacodynamic factors determining variations in propranolol responsiveness, in Beta-Adrenergic Blockade: A New Era in Cardiovascular Medicine, edited by Eugene Braunwald. Excerpta Medica pp 74-80, 1978.
6. Vestal RE Wood AJJ Branch RA Wilkinson GR Shand DG: Studies of drug disposition in the elderly using model compounds. In, The Liver and Aging, ed. K Ketani (Elsevier/North Holland) pp 343-358, 1978.
7. Shand DG Wood AJJ: Propranolol withdrawal syndromeXWhy? Circulation 58:202-203, 1978.
8. Shand DG Branch RA Wood AJJ Villeneuve JPA: Drug metabolism in experimental cirrhosis: the intact hepatocyte theory. In the Liver. Quantitative Aspects of Structure and Function. Ed. R. Presig, J. Birscher: 3rd International Gstaad Symposium, pp 346-350, 1978.

9. Wood AJJ: Pharmacodynamics of beta blockers. In, Current Concepts in Beta Adrenergic Blockade in the Management of Hypertension and Angina Pectoris, ed. E Rapaport (Biomedical Information Corporation: New York) pp 8-17, 1979.
10. O'Day DM Batchelor ED Wood AJJ Shand DG: Timolol maleateXA promising new beta adrenergic blocker for glaucoma. Australian Journal of Ophthalmology 7:19-22, 1979.
11. Berman R Cortin E Davidson MB Hench PK Murphy JP Reiff TR Wood AJJ: Update on the basic science of aging. Patient Care 13 (XV):24-67, 1979.
12. Berman R Cortin E Davidson MB Hench PK Murphy JP Reiff TR Wood AJJ: Five ways to easier geriatric diagnoses. Patient Care 13 (XVIII):91-157, 1979.
13. Wood AJJ Oates JA: Adverse reactions to drugs. In, Harrison's Principles of Internal Medicine, 9th Edition, etc. Petersdorf, et al (McGraw Hill: New York) pp 383-389, 1980.
14. Berman R Cortin E David MB Hench PK Murphy JP Reiff TR Wood AJJ: Treating the aging patient's cardiac problems. Patient Care 14 (II):98-130, 1980.
15. Berman R Cortin E Davidson MB Hench PK Murphy JP Reiff TR Wood AJJ: Tailoring therapies to physical age. Patient Care 14 (II):80-95, 1980.
16. Berman R Cortin E Davidson MB Hench PK Murphy JP Reiff TR Wood AJJ: Managing GI-GU disturbances in the elderly. Patient Care 14 (II):94-124, 1980.
17. Berman R Cortin E Davidson MB Hench PK Murphy JP Reiff TR Wood AJJ: Assessing connective tissue disease in old age. Patient Care 14 (III):126-157, 1980.
18. Vestal RE Wood AJJ: Influence of age and smoking on drug kinetics in man: Studies using model compounds. Clinical Pharmacokinetics 5:309-319, 1980.
19. Wood AJJ Feely J: Management of hypertension in the elderly. Southern Medical Journal 74:1503-1508, 1981.
20. Wood AJJ Feely J: Effect of age on sensitivity to drugs. In: Medicine in Old Age. (Churchill Livingstone), 1981.
21. Wood AJJ Feldman R Nadeau J: Physiological regulation of beta-receptors in man. Clinical and Experimental Hypertension, Part A, Theory and Practice 4:807-817, 1982.
22. Wood AJJ: Pharmacokinetics and pharmacodynamics of beta blockers. In The Evaluation of Beta Blockers and Calcium Antagonist Drugs. (Martinus Nijhoff: Boston) pp 41-61, 1982.
23. Wood AJJ Feely J: Pharmacokinetic drug interactions with propranolol. Clinical Pharmacokinetics 8:253-262, 1983.



24. Oates JA Robertson D Wood AJJ Woosley RL: Alpha and beta adrenergic agonists and antagonists. In: Cardiac Therapy. ( Martinus Nijhoff: Boston) pp 145-169, 1983.
25. Wood AJJ: Beta blocker withdrawal. Drugs 25 Supl 2:318-321, 1983.
26. Wood AJJ: How the beta blockers differ: A pharmacological comparison. Drug Therapy 13:59-72, 1983.
27. Wood AJJ Oates JA: Adverse reactions to drugs. In, Harrison's Principles of Internal Medicine, 10th Edition, (McGraw Hill: New York) pp 402-409, 1983.
28. Roden DM Wang T Woosley RL Wood AJJ Branch RA Kupfer A Wilkinson GR: Pharmacokinetic and pharmacological aspects of polymorphic drug oxidation in man. In: Pharmacokinetics, Eds. Benet, L.Z., Levy, G. and Ferraiolo, B.L., (Plenum Publishing Corporation) 1984.
29. Onrot J Wood AJJ: Hypertension in the elderly: The benefits of therapy. Postgraduate Medicine 76:46-49, 52-57, 1984.
30. Wood AJJ: Pharmacological differences between beta blockers. American Heart Journal 108:1070-1077, 1984.
31. Wood AJJ: Beta adrenoreceptors and aging. Therapeutics in the elderly: Scientific Foundations and clinical practice. O'Malley K, Waddington JL. Excerpta Medica 43-49, 1985.
32. Wood AJJ: Hypertension in the Elderly: Pharmacotherapy. (Biomedical Information Corp: New York) pp 213-223, 1986.
33. Wood AJJ: Pharmacologic Considerations in the elderly. In Coronary Heart Disease in the Elderly. Wenger, N.K., Furberg, C.D., Pitt, E. Elsevier New York, 1986.
34. Quart BD Gallo DG Sami MH Wood AJJ: Drug interaction studies and encainide use in renal and hepatic impairment. American Journal Cardiology 58:104C-113C, 1986.
35. Roden DM Wood AJJ Wilkinson GR Woosley RL: Disposition kinetics of encainide and metabolites. American Journal of Cardiology 58:4C-9C, 1986.
36. Wood AJJ: Beta receptor sensitivity testing in humans. Journal of Receptor Research 7:523-526, 1987.
37. Herd JA Wood AJJ Blumenthal J Dougherty JE Harris R: Medical therapy in the elderly. Journal of the American College of Cardiology 10:29A-35A, 1987.
38. Vestal RE Wood AJJ Abernethy DR Solomon DH Greenblatt DJ: The concept of geriatric clinical pharmacology. Panel I: The ideal training program. Clinical Pharmacology and Therapeutics 42:696-701, 1987.

39. Nace GS Wood AJJ: Pharmacokinetics of long acting propranolol. Implications for therapeutic use. Clinical Pharmacokinetics 13:51-64, 1987.
40. Kennedy HL Wood AJJ MacFarland RT: Drug interactions with Ethmozine (moricizine HC1). American Journal of Cardiology 60:79F-82F, 1987.
41. Wood AJJ Oates JA: Adverse reactions to drugs. In, Harrison's Principles of Internal Medicine, 11th Edition, (McGraw Hill: New York) pp 352-358, 1987.
42. Wood AJJ: Drug interactions in hypertension. Hypertension 11:II1-3, 1988.
43. Woosley RL Wood AJJ Roden DM: Drug therapy: Encainide. The New England Journal of Medicine 318:1107-1115, 1988.
44. Wood AJJ: Altered  $\beta$ -receptor responsiveness in aging: correlation of *in vivo* changes in sensitivity with *in vitro* changes in receptor function. From: Progress in Catecholamine Research Part C: Clinical Aspects, pages 413-415. Alan Liss, Inc., 1988.
45. Oates JA Wood AJJ: The regulation of discovery and drug development. The New England Journal of Medicine 320:311-312, 1989.
46. Wood AJJ: Calcium antagonists. Pharmacologic differences and similarities. Circulation 80(6 suppl):IV184-188, 1989.
47. Wood AJJ Zhou HH: Ethnic Differences in Drug Disposition and Responsiveness. Clinical Pharmacokinetics 20:350-373, 1991.
48. Wood AJJ Oates JA: Adverse reactions to drugs. In, Harrison's Principles of Internal Medicine, 12th Edition, (McGraw Hill: New York) pp 373-379, 1991.
49. Wood AJJ: Adverse reactions to drugs. In, Harrison's Principles of Internal Medicine, 13th Edition, (McGraw Hill: New York) 1993.
50. Wood AJJ: Pharmacogenetics and ethnicity as determinants of drug response. Anesthetic Pharmacology Review 1:343-353, 1993.
51. Alderman M Elliott WJ Oparil S Wood AJJ: Addressing multiple risks in hypertension therapy. Patient Care 28:64-76, 1994.
52. Wood AJJ: Mechanisms for interethnic differences in antihypertensive drug response. American Journal of Hypertension 8:128S, 1995.
53. Kinirons MT Wood AJJ: Pharmacokinetics. In, Drug Therapy in Old Age. (John Wiley & Sons, Chichester, England) pp 39-46, 1998.

54. Members of the Sicilian Gambit: Advances in Basic Research and Their Implications for Novel Antiarrhythmic Strategies. The Search for Novel Antiarrhythmic Strategies. Japanese Circulation Journal 62:633-648, 1998.
55. Members of the Sicilian Gambit: The Search for Novel Antiarrhythmic Strategies. European Heart Journal 19:1178-1196, 1998.
56. Wood AJJ: Ethnic Differences in Drug Disposition and Response. Therapeutic Drug Monitoring 20:525-526, 1998.
57. Wood AJJ Stein CM Woosley R: Making Medicines Safer: The need for an Independent Drug Safety Board. The New England Journal of Medicine 339:1851-1854, 1998.
58. Wood AJJ: The Safety of new Medicines: The importance of asking the right questions. Journal of the American Medical Association 281:1753-1754, 1999.
59. Editors of The New England Journal of Medicine: Looking Back on the Millennium in Medicine. The New England Journal of Medicine 342:42-50, 2000.
60. Wood AJJ: Thrombotic Thrombocytopenic Purpura and Clopidogrel - A Need for New Approaches to Drug Safety. The New England Journal of Medicine 342:1824-1826, 2000.
61. Xie HG Kim R Wood AJJ Stein CM: Molecular Basis of Ethnic Differences in Drug Disposition and Response. Annual Review of Pharmacology and Toxicology 41:815-850, 2001.
62. Wood AJJ: Racial Differences in the Response to Drugs - Pointers to Genetic Differences. The New England Journal of Medicine 344:1394-1396, 2001.
63. Stein CM Lang CC Xie HG Wood AJJ: Hypertension in black people: study of specific genotypes and phenotypes will provide a greater understanding of interindividual and interethnic variability in blood pressure regulation than studies based on race. Pharmacogenetics 11:95-110, 2001.
64. Wood AJJ: Adverse reactions to drugs. In, Harrison's Principles of Internal Medicine, 15th Edition, (McGraw Hill: New York) pp 430-438, 2001.
65. Wood AJJ: When increased therapeutic benefit comes at increased cost. The New England Journal of Medicine 346:1819-1821, 2002.
66. Wood AJJ: Variability in beta-adrenergic receptor response in the vasculature: role of receptor polymorphism. Journal of Allergy and Clinical Immunology: 110:S318-S321, 2002.
67. Wood AJJ: Aspirin, clopidogrel, or both for secondary prevention of coronary disease. The New England Journal of Medicine 348:563, 2003.

68. Drazen JM Green MF Wood AJ: The FDA, Politics and Plan B. The New England Journal of Medicine: 350:1565-1566, 2004.
69. Xie HG Wood AJJ Kim RB Stein CM Wilkinson GR: Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 5:243-272, 2004.

### **Communications and Abstracts**

1. Wood AJJ: Aplastic anemia in Scotland, an analysis of Scottish Hospital Morbidity Statistics. Scotland Medical Journal 17:376, 1972.
2. Wood AJJ O'Malley K Stevenson IH Ward CA Crooks J: Factors influencing the efficacy of anticoagulant drugs. Scotland Medical Journal 19:202, 1974.
3. Hedley AJ Hall J Kemp M Alexander E Deans weir R Bewsher PD Wood AJJ Downie WW Crooks J Knox J Dinwoodie DL Strong JA Alexander WD Knox J: A community based national follow-up register for patients treated for thyroid disease. World Conference on Medical Information (Medinfo 74) North Holland Publishing Company 463-466, 1974.
4. MacDonald M McCathe M Faed MJW Pringle R Goodall HB Beck JS Tudhope GR Mitchell PFL Wood AJJ Guthrie W Shaw D: Gaucher's Disease with biclonal gammopathy. Journal of Clinical Pathology 28:757, 1975.
5. Shand DG Kornhauser DM Wood AJJ Wilkinson GR Branch RA: Biological determinants of drug elimination in normal and cirrhotic men. Clinical Research 25:461A, 1977.
6. Wood AJJ Villeneuve JP Rogers LW Branch RA Shand DG: Drug metabolism in experimental cirrhosis in the rat: evidence for "sick cell" theory. Clinical Research 25:321A, 1977.
7. Branch RA Kornhauser DM Shand DG Wilkinson GR Wood AJJ: Biological determinants of propranolol disposition in normal subjects and patients with cirrhosis. British Journal of Clinical Pharmacology 4:630P-631P, 1977.
8. Wood AJJ Vestal RE Branch RA Wilkinson GR Shand DG: Age related effects of smoking on elimination of propranolol (P) antipyrine (Ap) and indocyanine green (ICG). Clinical Research 26:14A, 1978.
9. Wood AJJ Vestal RE Branch RA Wilkinson GR Shand DG: Age related effects of smoking on elimination of propranolol (P) antipyrine (Ap) and indocyanine green (ICG). Clinical Research 26:297A, 1978.

10. Vestal RE Wood AJJ Shand DG: Reduced beta-adrenoreceptor sensitivity in the elderly. Clinical Research 26:488A, 1978.
11. Wood AJJ Vestal RE Wilkinson GR Shand DG: Comparison of the bioavailability of propranolol during single and chronic oral dosing. Clinical Pharmacology and Therapeutics 23:137, 1978.
12. Wood AJJ Sharp RE Robers LN Shand DG Burr IM: Insulin removal by the perfused cirrhotic rat liver. Clinical Research 26:328A, 1978.
13. Vestal RE Wood AJJ Wilkinson GR Shand DG: The effects of age and smoking on the pharmacokinetics of propranolol in normal adult man. XI International Congress of Gerontology, page 62, 1978.
14. Vestal RE Wood AJJ Shand DG: The effect of age on the response to isoproterenol and on the affinity of propranolol for the beta-adrenergic receptor in man. XI International Congress of Gerontology, page 61, 1978.
15. Wood AJJ Vestal RE Branch RA Wilkinson GR Shand DG: Age related effects of smoking on elimination of propranolol, antipyrine and indocyanine green. Proceedings of VIIth International Congress of Pharmacology. Abstract 2301, p 737, 1978.
16. Branch RA Kornhauser DM Wilkinson GR Wood AJJ Shand DG: The influence of cirrhosis on free propranolol concentration during chronic oral administration. Proceedings of VIIth International Congress of Pharmacology. Abstract 2897, p 956, 1978.
17. Shand DG Vestal RE Wood AJJ: Reduced beta-adrenoreceptor sensitivity in the elderly. Proceedings of VIIth International Congress of Pharmacology. Abstract 2687, p 870, 1978.
18. Wood M Shand DG Wood AJJ: The effect of cardiopulmonary bypass on the binding of propranolol in man. Proceedings of the American Society of Anesthesiologists p. 515, 1978.
19. Wood M Shand DG Wood AJJ: The sympathetic response to profound hypothermia and circulatory arrest in infants. Proceedings of the American Society of Anesthesiologists. p. 333, 1978.
20. Wood M Berman L Wood AJJ Phythyon JM Hoyle P Harbison RD: Potentiation of halothane induced hepatic necrosis by triiodothyronine pretreatment. Toxicology and Applied Pharmacology 48:A142, 1979.
21. Wood M Shand DG Wood AJJ: Altered drug binding due to blood sampling through heparin locks. Clinical Pharmacology and Therapeutics 25:255, 1979.
22. Desmond P Roberts R Wilkinson G Wood AJJ Dunn D Schenker S: The effect of heparin on benzodiazepine binding in plasma. Federal Proceedings 38:743, 1979.

23. Wood AJJ Vestal RE Spannuth C Stone WJ Wilkinson GR Shand DG: Propranolol disposition in renal failure. Clinical Research 27:239A, 1979.
24. Wood M Berman ML Harbison RD Phythyon JM Wood AJJ: Halothane induced hepatic necrosis in hyperthyroid rats. Anesthesiology 51:S244, 1979.
25. Fraser JP Wood AJJ: Alterations in beta-receptor density following prolonged propranolol treatment. Circulation 60:II-274, 1979.
26. Wood AJJ Robertson RM Wilkinson GR Wood M: Effects of cardiac catheterization on the free levels of diazepam and propranolol. Circulation 60:II-264, 1979.
27. Wood AJJ Nadeau JH Robertson D Fraser J: Human leukocyte beta-receptors are normally down regulated by circulating catecholamines. Clinical Research 27:776A, 1979.
28. Fraser J Nadeau JH Robertson D Wood AJJ: Leukocyte beta-receptor density (Bmax) correlates with cardiac sensitivity to isoproterenol in man. Clinical Research 28:475A, 1980.
29. Nadeau JH Fraser J Robertson D Wood AJJ: Increased sodium intake increases sensitivity to catecholamines through alteration in receptor density. Clinical Research 28:240A, 1980.
30. Nadeau JH Fraser J Robertson D Wood AJJ: Effect of chronic propranolol treatment and withdrawal on urinary epinephrine and norepinephrine levels. Clinical Research 28:240A, 1980.
31. Fraser J Nadeau JH Robertson D Wood AJJ: Down regulation of human leukocyte beta-receptors by physiological levels of catecholamines. Clinical Research 28:541A, 1980.
32. Wood M Corke BC Killam AP Sundell H Wood AJJ: A model for the simultaneous determination of the factors controlling fetal and maternal concentrations of either drugs or endogenous compounds. Clinical Research 28:245A, 1980.
33. Wood M Berman ML Harbison RD Phythyon JM Wood AJJ: An animal model for halothane hepatotoxicity. Clinical Research 28:245A, 1980.
34. Wood M Wood AJJ: Differences in plasma drug binding in mother and newborn mediated by  $\alpha_1$  acid glycoprotein. Clinical Research 28:246A, 1980.
35. Wood AJJ Nadeau JH Fraser J: Increase in beta-receptor density following propranolol therapy. Proceedings of the World Congress on Clinical Pharmacology and Therapeutics. Abstract 126, 1980.
36. Wood AJJ Nadeau JH Robertson D Fraser J: Control of beta-receptor function in man. Proceedings of the World Congress on Clinical Pharmacology and Therapeutics. Abstract 127, 1980.

37. Wood M Robertson D Robertson RM Wilkinson GR Wood AJJ: Free levels of diazepam and propranolol during cardiac catheterization. World Congress of Clinical Pharmacology. Abstract 125 London, 1980.
38. Wood M Berman ML Harbison RD Phythyon JM Wood AJJ: Triiodothyronine sensitizes the rat to halothane hepatotoxicity. World Congress of Clinical Pharmacology. Abstract 702 London, 1980.
39. Wood M Berman ML Harbison RD Phythyon JM Wood AJJ: An animal model for halothane hepatotoxicity. Abstract of 7th World Congress of Anesthesiology, Hamburg, p. 544, 1980.
40. Wood M Stone WJ Wood AJJ: Plasma binding of pancuroniumXeffect of age, sex and disease. Anesthesiology 53:S-286, 1980.
41. Wood M Wood AJJ: Differences in plasma binding in mother and newborn mediated by alpha<sub>1</sub> acid glycoprotein. Pharmacologist 22:189, 1980.
42. Wood AJJ Phythyon JM Uetrecht J Nakamura K Wood M: Reductive metabolism not a prerequisite for triiodothyronine induced halothane hepatotoxicity. Pharmacologist 22:228, 1980.
43. Feely J Wilkinson GR Wood AJJ: Cimetidine administration results in increased effects of propranolol and higher blood levels. Circulation 62:II-257, 1980.
44. Duff HJ Roden DM Smith RF Dawson A Wood AJJ Oates J Woosley RL: Electrophysiologic actions of high dose propranolol independent of beta blockade. Circulation 62:III-11, 1980.
45. Wood AJJ: Assessment of beta-receptor down regulation in man. Clinical Pharmacology and Therapeutics. Proceedings of the First World Congress. MacMillan, London, 175-178, 1980.
46. Robertson D Wood AJJ Bernard Y Robertson RM: Propranolol in vasotonic angina pectoris. Clinical Research 28:813A, 1981.
47. Woosley RL Roden DM Duff HJ Carey EL Wood AJJ Wilkinson GR: Co-inheritance of deficient oxidative metabolism of encainide and debrisoquine. Clinical Research 29:501A, 1981.
48. Feely J Wilkinson GR Wood AJJ: Cimetidine Reduces Apparent Liver Blood Flow in Man. Clinical Research 28:882A, 1981.
49. Feely J Nakamura K Branch RA Wilkinson GR Wood AJJ: Influence of Furosemide on the Disposition of Propranolol. Clinical Research 28:817A, 1981.

50. Feldman R Nadeau J Limbird L Robertson D FitzGerald G Wood AJJ: Dynamic regulation of beta-adrenergic receptor agonist affinity by physiological changes in catecholamines. Clinical Research 29:859A, 1981.
51. Wood M Uetrecht J Phythyon JM Wood AJJ: Effect of sex, starvation and deuterium (d) substitution on triiodothyronine (T<sub>3</sub>) induced halothane (H) hepatotoxicity. Pharmacologist 23: Abstract 563 p. 221, 1981.
52. Feely J Nakamura K Branch RA Wilkinson GR Wood AJJ: Increased clearance of propranolol due to furosemide. Clinical Research 29:189A, 1981.
53. Wells PG Feely J Nadeau J Wilkinson GR Wood AJJ: Propranolol disposition in thyrotoxicosis. Clinical Research 29:279A, 1981.
54. Feely J Wilkinson GR Wood AJJ: Reduction in liver blood flow produced by acute and chronic cimetidine. Clinical Research 29:270A, 1981.
55. Feely J McAllister CB Wilkinson GR Wood AJJ: Reduction in lidocaine clearance by cimetidine. British Journal of Clinical Pharmacology 13:591P-592P, 1982.
56. Feely J Wood AJJ: Reduction in apparent liver blood flow in man by histamine receptor blockers and inhibition of prostaglandin synthesis. British Journal of Clinical Pharmacology 13:592P-593P, 1982.
57. Feely J Wood AJJ: Cimetidine Ethanol Interaction. British Journal of Clinical Pharmacology 14:146P, 1982.
58. Wood M Uetrecht J Phythyon JM Wood AJJ: Cimetidine Protects Against Halothane-induced Hepatotoxicity. Anesthesiology 57:A221, 1982.
59. Wood M Wood AJJ: Contrasting effects of inhalational anesthetics on in vivo drug metabolism. Anesthesiology 57:A245, 1982.
60. Feely J Nadeau J Wood AJJ: Food induced alterations in the systemic clearance of drugs. British Journal of Clinical Pharmacology 14:599p, 1982.
61. Wood M Utrecht J Phythyon JM Wood AJJ: Protective effect of diethylmaleate on triiodothyronine induced halothane hepatotoxicity. Federation Proceedings 41:1052, 1982.
62. Wang T Roden DM Wolfenden HT Woosley RL Wilkinson GR Wood AJJ: Pharmacokinetics of encainide and its metabolites in man. Clinical Pharmacology and Therapeutics 31:278, 1982.
63. FitzGerald GA Robertson D Wood AJJ: Biphasic regulation of  $\beta$ -adrenoreceptor density by epinephrine and norepinephrine infusion in man. Clinical Pharmacology and Therapeutics 31:225, 1982.



64. Feldman R Nadeau J Limbird L Robertson D FitzGerald GA Wood AJJ: Modulation of beta adrenoreceptor affinity and response parallels dynamic changes in human sympathetic activity. Clinical Research 30:251A, 1982.
65. Dawson AK Wood AJJ Woosley RL Duff HL Smith RF: Electrophysiologic effects of D and DL-propranolol matched for  $\beta$ -blockade: Evidence *in vivo* for effects not mediated by the  $\beta$ -adrenoreceptor. Clinical Research 30:181A, 1982.
66. Feldman R Limbird LE Nadeau J Robertson D Wood AJJ: Alteration in beta adrenergic receptor-agonist interactions in hypertension. Circulation 66:II-207, 1982.
67. Herman RJ Nakamura K Wilkinson GR Wood AJJ: Induction of propranolol metabolism in man by rifampin. The Pharmacologist 24:181 (1982).
68. Duff HJ Wood AJJ Dawson AK Roden DM Primm RK Smith RF Woosley RL: d-Propranolol: Non-adrenergically mediated electrophysiologic actions in man. Circulation 66:II-372, 1982.
69. Feely J Wood AJJ: Reduction in apparent liver blood flow in man by histamine receptor blockers and inhibition of prostaglandin synthesis. British Journal of Clinical Pharmacology 13:592p-593p, 1983.
70. Feldman R FitzGerald GA Nadeau J Robertson D Wood AJJ: Time course of the regulation of leukocyte beta-receptors by catecholamines. Clinical Pharmacology and Therapeutics 33:204, 1983.
71. Riddell JG McAllister CB Wilkinson GR Wood AJJ Roden DM: A new simple method for rapidly achieving constant plasma drug concentrations: application to lidocaine. Clinical Pharmacology and Therapeutics 33:260, 1983.
72. Feldman R Limbird LE Nadeau J Robertson D Wood AJJ: Alterations in beta adrenergic receptor-agonist interactions with ageing. Clinical Research 31:247A, 1983.
73. Wood M Wood AJJ: Alteration in anesthetic defluorination by cimetidine. Anesthesiology 59:A256, 1983.
74. Wood AJJ: Aging and drugs that influence noradrenergic systems in man. Satellite to Second World Congress on Clinical Pharmacology and Therapeutics August, 1983.
75. Raghuram TC Wilkinson GR Koshakji R Wood AJJ: Genetic polymorphism of propranolol metabolism. Second World Conference on Clinical Pharmacology and Therapeutics Washington, Abstract No. 656, 1983.
76. Bergstrand RH Wang T Roden DM Avant GR Sutton WW Siddoway LA Wolfenden H Woosley RL Wilkinson GR Wood AJJ: Effect of liver disease on encainide disposition.

Second World Conference on Clinical Pharmacology and Therapeutics Washington, Abstract No. 60, 1983.

77. Wood M Wood AJJ: Effects of anesthesia on drug metabolism in vivo. Second World Conference on Clinical Pharmacology and Therapeutics Washington, Abstract No. 666, 1983.
78. Hammon JW Jr Wood AJJ Prager RL Wood M Muirhead J Bender HW Jr: Perioperative beta blockade with propranolol: Reduction in myocardial oxygen demands and the incidence of atrial and ventricular arrhythmias. Annals of Thoracic Surgery 36:372, 1983.
79. Nadeau JH FitzGerald GA Oates JA Wood AJJ: The effects of converting enzyme inhibition (CEI) on sodium balance and systemic prostacyclin (PGI<sub>2</sub>) synthesis in man. Clinical Research 31:844A, 1984.
80. Multicenter Study Group: Combined labetalol and hydrochlorothiazide therapy in hypertension. Labetalol/HCTZ. Clinical Research 32:335A, 1984.
81. Nadeau J FitzGerald GA Oates JA Wood AJJ: The effects of converting enzyme inhibition on sodium balance and systemic prostacyclin synthesis in man. Clinical Research 32:336A, 1984.
82. Reilly CS Wood M Wood AJJ: Comparative potencies of esmolol, a short-acting beta-blocker, and propranolol in man. Anesthesiology 61:A18, 1984.
83. Wood M Uetrecht J Sweetman B Wood AJJ: Effect of cimetidine on the oxidative metabolism of halothane. Anesthesiology 61:A269, 1984.
84. Reilly CS Wood AJJ Koshakji R Wood M: The effect of halothane on drug disposition: Contributions of hepatic metabolism and blood flow. Anesthesiology 61:A529, 1984.
85. Thompson KA Roden DM Wood AJJ Siddoway LA Barbey T Woosley RL: Suppression of ventricular arrhythmias by dextro-propranolol in man. Circulation 70: II-441, 1984.
86. Reilly CS Wood AJJ Wood M: Variability of Fentanyl Kinetics in Man: Computer predicted plasma concentrations for three intravenous dosage regimens. IUPHAR 9th International Congress of Pharmacology London, Abstracts, 1767P, 1984.
87. Biollaz J Shaheen O Wood AJJ: Cimetidine reduces ethmozine clearance. IUPHAR 9th International Congress of Pharmacology London, Abstracts, 934P, 1984.
88. Bergstrand RH Wang T Stone WJ Wilkinson GR Wolfenden HT Roden DM Woosley RL Wood AJJ: Encainide Disposition in Renal Failure. Clinical Pharmacology and Therapeutics 37:182, 1985.
89. Reilly CS Wood M Koshakji R Wood AJJ: Comparative Potency of Intravenous Esmolol and Oral Propranolol. Clinical Pharmacology and Therapeutics 37:223, 1985.

90. Shaheen O Patel J Avant G Wood AJJ: Pinacidil Kinetics and Dynamics is Independent of Debrisoquine Phenotype. Clinical Pharmacology and Therapeutics 37:228, 1985.
91. Gordon L Wood AJJ Wood M: Acute effects of halothane on drug distribution in the dog. Anesthesia and Analgesia 64:217, 1985.
92. Reilly CS Wood M Koshakji RP Wood AJJ: Is propranolol really more effective by the oral than intravenous route. Circulation 72:III-52, 1985.
93. Reilly CS Wood AJJ Koshakji R Wood M: The Effect of Fentanyl-Anesthesia on Drug Disposition. Anesthesiology 63:A280, 1985.
94. Rigby JW Nadeau J Wood AJJ: Inadequate incubation times artifactually increase K<sub>d</sub> for ICYP binding to human lymphocyte beta adrenergic receptors. Pharmacologist 27:239, 1985.
95. Wood AJJ: Changes in responses to drugs acting on beta receptors in aging. Proceedings of the 6th International Symposium on Methods in Clinical Pharmacology 137-142, 1985.
96. Nace GS Wood AJJ: Exercise-induced increase in beta-adrenergic receptor (BAR) density is prevented by beta blockade. Clinical Research 34:406A, 1986.
97. Rigby JW Wood AJJ: Direct determination of high affinity  $\beta$ -adrenergic receptors for agonists on human mononuclear leukocyte membranes. Clinical Research 34:406A, 1986.
98. Merrell WJ Reilly CS Koshakji R Wood AJJ Wood M: The effect of isoflurane anesthesia on drug disposition. Clinical Research 34:403A, 1986.
99. Gordon L Wood AJJ Wood M: Acute effects of halothane on the distribution of propranolol in the dog. Proceedings of World Congress on Clinical Pharmacology and Therapeutics Abstract 569, 1986.
100. Herman RJ Biollaz J Shaheen O Wood AJJ Wilkinson GR: Induction of propranolol metabolism by rifampin in the elderly. Proceedings of the World Congress on Clinical Pharmacology and Therapeutics Abstract 274, 1986.
101. Shaheen O Patel J Avant GR Hamilton M Wood AJJ: Effect of cirrhosis and debrisoquine phenotype on the disposition and effects of pinacidil. Clinical Pharmacology and Therapeutics 40:650-655, 1986.
102. Merrell WJ Rodeheffer RJ Nadeau JH Wood AJJ: Simultaneous assessment of  $\alpha$  and  $\beta$  adrenergic receptor function in man. Clinical Research 35:9A, 1987.
103. Anthony L Koshakji R Wilkinson GR Wood AJJ: Multiple pathways of propranolol's metabolism are inhibited by debrisoquine. Clinical Research 35:8A, 1987.

104. Shaheen O Biollaz J Koshakji R Wilkinson GR Wood AJJ: Influence of debrisoquine (D) phenotype on the inducibility of propranolol (P) metabolism. Clinical Pharmacology and Therapeutics 41:158, 1987.
105. Anthony LB Wood AJJ Hande K: Longitudinal effects of cyclophosphamide on aminopyrine and antipyrine metabolism. Clinical Research 35:373A, 1987.
106. Merrell WJ Rodeheffer RJ Nadeau JH Wood AJJ: Simultaneous assessment of  $\alpha$  and  $\beta$  adrenergic receptor function in man. Clinical Research 35:378A, 1987.
107. Zhou HH Anthony LB Wood AJJ Wilkinson GR: Induction by rifampin of genetically determined 4-hydroxylation of S-mephenytoin in man. Clinical Pharmacology and Therapeutics 43:135, 1988.
108. Zhou HH Koshakji RP Wood AJJ: Ethnic differences in the pharmacokinetics of propranolol (P). Clinical Pharmacology and Therapeutics 43:161, 1988.
109. Silberstein DJ Rigby JW Merrell WJ Wood AJJ: Aging is not associated with altered beta adrenoreceptor internalization. Clinical Research 36:369A, 1988.
110. Silberstein DJ Zhou HH Koshakji RP Wood AJJ: Lymphocyte beta adrenergic receptor density predicts the extent of beta blockade *in vivo*. Clinical Research 36:369A, 1988.
111. Whelan E Wood AJJ Blair I Koshakji RP Wood M: Halothane anesthesia differentially reduces the clearance of d and l propranolol. Clinical Research 36:370A, 1988.
112. Zhou HH Koshakji RP Silberstein DJ Wood AJJ: Ethnic differences in sensitivity to propranolol induced beta-blockade. Clinical Research 36:370A, 1988.
113. Merrell WJ Naslund TC Nadeau JH Wood AJJ: Alpha receptor blockade makes minimal contribution to ketanserin's hypotensive effect. Clinical Research 36:429A, 1988.
114. Naslund TC Merrell WJ Silberstein DJ Nadeau JH Wood AJJ: High salt diet increases vascular sensitivity to beta adrenergic vasodilation. Clinical Research 36:430A, 1988.
115. Funck-Brentano C Silberstein DJ Wood AJJ Roden DM Woosley RL: D-sotalol-induced changes in heart rate are not due to  $\beta$ -adrenergic blockade. Circulation 78:II-499, 1988.
116. Naslund TC Silberstein DJ Merrell WJ Nadeau JH Wood AJJ: Hypertensives fail to increase sensitivity to  $\beta$  receptor mediated vasodilation during increased sodium intake. Circulation 78:II-173, 1988.
117. Kroemer H Silberstein DJ Woosley RL Eichelbaum M Wood AJJ Roden DM: Effects of propafenone enantiomers on sodium conductance and beta-blockade. Circulation 78:II-349, 1988.

118. Zhou HH Anthony LB Roden D Wood AJJ: Evaluation of cardiac response to propranolol-quinidine combination. Clinical Research 37:10A, 1989.
119. Zhou HH Anthony LB Roden D Wood AJJ: Quinidine stereoselectively alters the disposition of propranolol. Clinical Research 37:10A, 1989.
120. Wood M Whelan E Shay S Wood AJJ: Acute effect of halothane (H) on drug distribution. Anesthesiology 71:3A, 1989.
121. Zhou HH Anthony LB Roden R Wood AJJ: Cardiac interaction of propranolol and quinidine combination. Clinical Research 37:342A, 1989.
122. Zhou HH Anthony LB Roden D Wood AJJ: Stereoselective alteration of propranolol disposition by quinidine. Clinical Research 37:343A, 1989.
123. Bluhm R Bobbitt RG Bonfiglio JF Branch RA Sarzen C Welch L Wood AJJ Heath AJ: 2,3-Dimercaptosuccinic acid (DMSA) vs N-acetyl-penicillamine (NAP) for the treatment of elemental mercury toxicity. 1989 AAPCC/AACCT/ABMT/CAPCC Annual Scientific Meeting.
124. Zhou HH Wood AJJ: Propranolol suppresses exercise induced rise in renin more in Chinese than Caucasians. Clinical Pharmacology and Therapeutics 47:141, 1990.
125. Zhou HH Wood AJJ: Atropine produces a greater increase in heart rate in Chinese than Caucasians. Clinical Research 38:7A, 1990.
126. Zhou HH Wood AJJ: Sensitivity to propranolol is increased in Chinese even in the absence of vagal activity. Clinical Research 38:7A, 1990.
127. Goldner DN Hasan S Lichtenstein MJ Shiavai R Wood AJJ: Dose related effect of triazolam on postural sway. Clinical Research 38:419A, 1990.
128. Zhou HH Wood AJJ: Chinese are more sensitive to renin suppression by propranolol and to anticholinergic effects of atropine. European Journal of Pharmacology 183:1650-51, 1990.
129. Bluhm RE Welch LW Bobbitt RG Bonfiglio JF Wood AJJ Branch RA: Acute elemental mercury exposure induces dose related persistent neuropsychological sequelae in man. Annual Scientific Meeting AACCT/AAPCC/ABMT/CAPCC 1990.
130. Hasan SS Goldner DN Lichtenstein MJ Wood AJJ Shiavi RG: Selecting a suitable biomechanics platform measure of sway. Proc IEEE-EMBS 12:2105-2106, 1990.
131. Deegan R Wood AJJ Wood M: Dual action of halothane on sympathetic function: Decrease in NE release and clearance. Anesthesiology 73:A591, 1990.

132. Zhou HH Sheller JR Wood M Wood AJJ: Caucasians are more sensitive than Chinese to the cardiovascular and respiratory effects of morphine but less to the gastrointestinal side effects. Clinical Research. 38:968A, 1990.
133. Deegan R He HB Wood AJJ Wood M: Propofol markedly inhibits sympathetic activity: Assessment of NE kinetics in dogs. Anesthesia and Analgesia 72:549, 1991.
134. Zhou HH Shay SD Wood AJJ: Ethnic differences in stereoselective binding of propranolol. Clinical Pharmacology and Therapeutics 49:177, 1991.
135. Zhou HH Wilkinson GR Wood AJJ: Phenotypic effects on the ability to induce debrisoquine metabolism. Clinical Pharmacology and Therapeutics 49:175, 1991.
136. Zhou HH Sheller JR Wood M Wood AJJ: Ethnic differences in response to morphine (M). Clinical Research 39:301A, 1991.
137. Bluhm RE Breyer J Bobbitt RG Welch LW Wood AJJ Bonfiglio JF Branch RA: Hyperchloremia as a manifestation of elemental mercury vapor toxicity in chloralkali workers. Veterinary and Human Toxicology 33:373, 1991.
138. Zhou HH Wood AJJ: The stereoselective inhibition of propranolol metabolism by quinidine is phenotype dependent. Clinical Research 39:264A, 1991
139. Stein CM Deegan RJ Wood AJJ: Vascular beta adrenergic responsiveness is desensitized by chronic exposure to terbutaline. Clinical Research 39:832A, 1991.
140. Zhou HH Sheller JR Wood M Wood AJJ: Ethnic difference in morphine 3-glucuronidation between Chinese and Caucasians. Clinical Research 40:325A, 1992.
141. Stein CM Deegan RJ Wood AJJ: Human vascular smooth muscle responsiveness to beta adrenergic agonist in vivo is desensitized by chronic exposure to terbutaline. Clinical Research 40:326A, 1992.
142. Edeki T Wood AJJ: Inhibition of cytochrome P450 II D6 by quinidine increased the cardiovascular effects of timolol eye drops. Clinical Research 40:162A, 1992.
143. Kinirons MT O'Shea DD Wilkinson GR Wood AJJ: *In vivo* probes of cytochrome P4503A function in normal subjects: Comparison of the erythromycin breath test and urinary dapsone recovery. Clinical Research 40:781A, 1992.
144. Caraco Y Sheller JR Wood AJJ: Polymorphic drug metabolism and codeine pharmacodynamics Clinical Research 40:781A, 1992.
145. Deegan R He HB Krivoruk Y Wood AJJ Wood M: Halothane inhibits presynaptic  $\beta$ -2 induced norepinephrine (NE) release in vivo. Anesthesiology 77:A622, 1992.

146. Hasan SS Robin DW Shiavi RG Wood AJJ: New measures of postural sway used in evaluating drug effect. Journal of the American Geriatric Society 40:SA26, 1992.
147. Morike K Fish FA Mosqueda-Garcia R Smith M Wood AJJ Roden D: Sympathetic activity: A modulator of quinidine disposition? Clinical Pharmacology and Therapeutics 53:169, 1993.
148. Edeki TI Wood AJJ: The cardiovascular effects of timolol eye drops in extensive and poor debrisoquine metabolizers Clinical Pharmacology and Therapeutics 53:157, 1993.
149. Robin DW Lee MH Hasan S Wood AJJ: Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clinical Research 41:126A, 1993.
150. Caraco Y Sheller JR Wood AJJ: Polymorphic drug metabolism and codeine pharmacodynamics. Clinical Research 41:204A, 1993.
151. Caraco Y Sheller JR Wood AJJ: The effect of rifampin on codeine pharmacokinetics and pharmacodynamics. Clinical Research 41:204A, 1993.
152. Kinirons MT O'Shea DD Groopman JD Wilkinson GR Wood AJJ: Putative *in vivo* probes of cytochrome P4503A function in normal subjects: The erythromycin breath test, urinary dapsone recovery ration and urinary 6  $\beta$ -hydroxycortisol excretion ratio. Clinical Research 41:203A, 1993.
153. Krivoruk Y Kinirons M Wood AJJ Wood M: Alfentanil metabolism *in vivo* does not correlate with the erythromycin breath test (ERBT). The Pharmacologist. 35:202, 1993.
154. Robin DW Hasan SS Edeki T Lichtenstein MJ Shiavi RG Wood AJJ: The effects of age on traizolam induced postural sway. Journal of the American Geriatric Society 41:SA5, 1993.
155. Krivoruk Y Deegan R He HB Wood AJJ Wood M: Increase in norepinephrine spillover precedes anesthesia induction: Implication for perioperative ischemia. Annual Meeting of Society of Cardiovascular Anesthesiologists. p. 246. 1993 proceedings.
156. Nelson R Wood M Wood AJJ He HB Stewart JR: Norepinephrine concentrations increase during cardiopulmonary bypass because of change in norepinephrine release and not clearance. Anesthesiology 79:A85, 1993.
157. Caraco Y Wilkinson GR Wood AJJ: In vivo screening for P450 Mediated Drug Interactions with Omeprazole. Clinical Pharmacology and Therapeutics 55:209, 1994.
158. Caraco Y Tateishi T Wood AJJ: Ethnic effects on inhibition of drug metabolism. Clinical Pharmacology and Therapeutics 55:169, 1994.
159. Kinirons M Morike K Shay S Roden D Wood AJJ: Does selective inhibition of cytochrome P450s Occur with aging? Clinical Research 42:215A, 1994

160. Stein C He H Pincus T Wood AJJ: Cyclosporine impairs vasodilation without altering sympathetic activity. Clinical Research 42:252A, 1994.
161. Stein CM Nelson R Deegan R He H Inagami T Frazer M Badr K Wood M Wood AJJ: Acute exposure to agonist does not result in desensitization of presynaptic or postsynaptic beta adrenergic receptor-mediated responses. Clinical Research 42:252A, 1994.
162. Kinirons M Lang C Robin D Shay S Wood AJJ: Ethnicity and CYP3A4 activity: Triazolam pharmacokinetics and pharmacodynamics in Caucasians and Asian Indians. Clinical Research 42:253A, 1994.
163. Lang C Choy A Roden D Robertson D Wood AJJ Biaggioni I: Abnormal QT interval and dispersion in primary disorders of autonomic failure. Clinical Research 42:258A, 1994.
164. Kinirons MT O'Shea D Groopman JD Thummel KE Wood AJJ Wilkinson GR: Route of administration does not explain the lack of correlation between putative *in vivo* probes of cytochrome P4503A. British Journal of Clinical Pharmacology 37:501P-502P, 1994.
165. Krivoruk Y Kinirons M Wood AJJ Wood M: Alfentanil disposition *in vivo* is mediated by CYP3A4 in humans. Anesthesiology 81:A380, 1994.
166. Krivoruk Y O'Shea D Wilkinson GR Wood AJJ Wood MD: Metabolism of alfentanil and dapsone In Vivo: Additional evidence for existence of multiple isoforms of CYP3A4. Canadian Journal of Physiology and Pharmacology 72:P12.3.33, 1994.
167. Tateishi T Krivoruk Y Wood AJJ Guengerich FP Wood M: Identification of human liver P450 3A4 as the enzyme responsible for sufentanil N-dealkylation. Canadian Journal of Physiology and Pharmacology 72:P12.3.34, 1994.
168. Lang CC Biaggioni I Stein CM Roden DM Robertson D He HB Choy AM Nelson R Wood AJJ: Effects of acute and chronic sympathetic withdrawal on QT interval in humans. Circulation 90:3559:PI-661, 1994.
169. Stein CM Nelson RA Brown RM Wood M Wood AJJ: Dietary sodium intake modulates vasodilation mediated by nitroprusside but not by methacholine in the Human Forearm. Circulation 90:2766:PI-514, 1994.
170. Tateishi T Ueng Y-F Wood AJJ Guengerich FP Wood M: Identification of human liver CYP3A4 as the enzyme responsible for fentanyl and sufentanil N-dealkylation. Anesthesia and Analgesia. 80:S493, 1995.
171. Caraco Y Lagerstrom PO Wood AJJ: Omeprazole disposition in Caucasian and Chinese Subjects. Clinical Pharmacology and Therapeutics 57:216, 1995.



172. Lang CC Stein CM Brown RM Deegan R Nelson R Wood AJJ: Normotensive blacks have impaired  $\beta_2$ -adrenoreceptor mediated vasodilation. Clinical Pharmacology and Therapeutics 57:205, 1995.
173. Stein CM Nelson R Deegan R He HB Wood M Wood AJJ: Forearm  $\beta_2$  receptor-mediated vasodilation is impaired in borderline hypertension. Clinical Pharmacology and Therapeutics 57:194, 1995.
174. Stein CM Kinirons MT Pincus T Wilkinson GR Wood AJJ: Pharmacological probes of cytochrome P4503A activity and cyclosporine concentrations. Clinical Pharmacology and Therapeutics 57:192, 1995.
175. Kinirons MT Krivoruk Y Wilkinson GR Wood AJJ: Cytochrome P4503A and the dapsone recovery ratio: Lack of inhibition by ketoconazole. Clinical Pharmacology and Therapeutics 57:186, 1995.
176. Wood AJJ Stein CM He HB Lang CC: Effect of angiotensin converting enzyme inhibition on sympathetic activity in healthy subjects. Clinical Pharmacology and Therapeutics 57:167, 1995.
177. Lang CC Stein CM Nelson R He HB Wood M Wood AJJ: Effects of  $\alpha_2$ -stimulation are blunted in chronic heart failure. Clinical Pharmacology and Therapeutics 57:142, 1995.
178. Brown RM Tateishi T Guengerich FP Wood M Wood AJJ: Halothane microsomal oxidation is inhibited by diethyldithiocarbamate (DDC), an inhibitor of CYP2E1. Anesthesia and Analgesia 80:S59, 1995.
179. Lang CC Rayos GH Gothard P Yeoh TK Stein CM Wood AJJ Wilson J: Effect of sympathoinhibition on limb circulation and metabolism during exercise in patients with heart failure. Circulation 92: I-273, 1995.
180. Lang CC Kinirons MT Shay S Ghebreslasie K Robin DR Wood AJJ: Evidence of increased CYP3A4 activity in African Americans. Clinical Pharmacology and Therapeutics (Submitted), 1995.
181. Caraco Y Lagerstrom P Wood AJJ: Ethnic and Genetic Determinants of Omeprazole Disposition and Effect. Clinical Pharmacology and Therapeutics 216:OIII-A3, 1996.
182. Lang CC Kinirons MT Robin DR Wood AJJ: Evidence of increased CYP3A4 activity in African Americans. Clinical Pharmacology and Therapeutics 158:OI-B-1, 1996.
183. Stein CM Nelson RA He HB Wood M Wood AJJ: Delayed effects of epinephrine on systemic and local norepinephrine release. Clinical Pharmacology and Therapeutics 139:PI-40, 1996.
184. Stein CM Brown N Carlson M Campbell P Wood AJJ: Co-Administration of glyburide and minoxidil, drugs with opposing effects on potassium channels. Clinical Pharmacology and Therapeutics 139, PI-39, 1996.

185. Lang CC Stein CM He HB Wood JJ: Blunted blood pressure response to central sympatho-inhibition in normotensive blacks. Journal of Hypertension S106, 14:5106, 1996.
186. Robin DW Mayo G Anderson A Burger MC Wood AJJ: Age and gender effects on the disposition and response to ethanol. Journal of Investigative Medicine 45:259A, 1997.
187. Brown NJ Wood AJJ Robin DW: Gender-specific effect of alcohol on catecholamines. Journal of Investigative Medicine 45:276A, 1997.
188. Stein CM Brown NJ Vaughan DE Lang CC Wood AJJ: Vascular regulation of tissue plasminogen activator release. Circulation 96:I-43, 1997.
189. Kim RB Wandel C Leake B Waldrop H Coffey R Wood AJJ Wilkinson GR: P-Glycoprotein-mediated Drug Transport by Caco-2 Cells. Clinical Investigative Medicine 20:S12, 1997.
190. Kim RB Wandel C Leake B Waldrop H Wood AJJ Wilkinson GR: Differences in substrate affinities for CYP3A isoforms using a recombinant Vaccinia expression system. Clinical Investigative Medicine 20:S12, 1997.
191. Stein CM Lang CC Singh I Wood AJJ: Increased alpha-adrenergic sensitivity in African-Americans. Clinical Pharmacology & Therapeutics 63:176, 1998.
192. Kim RB Leake B Cvetkovic M Wandel C Roden MM Fromm MF Chaudhary AK Belas F Roden DM Wood AJJ Wilkinson GR: Transport of P450 (CYP) Drug Substrates by P-Glycoprotein. Clinical Pharmacology and Therapeutics 63:206, 1998.
193. Wandel C Kim RB Kajiji S Guengerich FP Wood AJJ: Effects of P-Glycoprotein (P-GP) Inhibitors on CYP3A. Clinical Pharmacology and Therapeutics 63:206, 1998.
194. Xie HG Kim RB Stein CM Wood AJJ: Distribution of Genetic Polymorphisms of B2-Adrenoceptor Gene Between Black and White Populations. Clinical Pharmacology and Therapeutics 63:156, 1998.
195. Stein CM Lang CC Singh I He HB Wood AJJ: Increased Vasoconstriction and Decreased Vasodilation not Increased Sympathetic Activity are Mechanisms for Enhanced Vascular Reactivity in African-Americans. Circulation 98:I 472-473, 1998.
196. Wood AJJ: Interethnic Differences in Drug Response. Archives of Pharmacology S1:358:1:R14, 1998.
197. Kim RB Xie HG Stein CM Gainer JV Brown NJ Wood AJJ: Differences in the frequency of Arg492|Cys polymorphism of the human  $\alpha$ 1A adrenergic receptor in African-Americans and Caucasians. Clinical Pharmacology and Therapeutics OIII-A-3, 1999.

198. Xie HG Kim RB Stein CM Gainer JV Brown NJ Leake B Wood AJJ: Beta-2 adrenergic receptor polymorphism is not associated with hypertension in African-Americans or Caucasians. Clinical Pharmacology and Therapeutics PI-41, 1999.
199. Xie HG Kim RB Stein CM Gainer JV Brown NJ Leake B Xiao ZS He N Shoue HH Wood AJJ: Interethnic differences in beta-2 adrenergic receptor polymorphisms in African-Americans, Caucasian and Chinese populations. Clinical Pharmacology and Therapeutics PI-65, 1999.
200. Stein CM Murray JJ Wood AJJ: A rapid pharmacodynamic measure to determine interindividual variability in response to cyclosporine. Clinical Pharmacology and Therapeutics PII-53, 1999.
201. Stein CM Murray JJ Wood AJJ: Cyclosporine pharmacokinetics and pharmacodynamics in African-Americans and Caucasians. Clinical Pharmacology and Therapeutics PII-52, 1999.
202. Sofowora GG Singh I Stein CM He H Wood AJJ: Adrenergic responses in postmenopausal women: no evidence of modulation by estrogen. Clinical Pharmacology and Therapeutics PII-13, 1999.
203. Caraco Y Sheller J Wood AJJ: Ethnic variability in the effect of rifampin on codeine disposition and pharmacodynamics. Clinical Pharmacology and Therapeutics s 67:98, 2000.
204. Wandel C Kim RB Wood AJJ Wood M: Interaction between p-glycoprotein and opioids. Anesthesiology 91:No. 3A:A445, 1999.
205. Schwarz UI Choo EF Dresser GK Stein CM Wood AJJ Roden DM Wilkinson GR Kim RB: Identification of a new CYP2C9 variant in African-Americans. Clinical Pharmacology and Therapeutics 67:169, 2000.
206. Wandel C Hall JM Stein CM Wood AJJ Wilkinson GR: CYP3A Activity is similar in African-Americans and Caucasian men. Clinical Pharmacology and Therapeutics 67:152, 2000.
207. Dishy V Sofowora G Kandcer M Zhan F Wood AJJ Stein CM: The Effect of sildenafil citrate on nitric oxide-mediated vascular responses. Clinical Pharmacology and Therapeutics 67:141, 2000.
208. Xie HG Stein CM Kim RB Sofowora G Dishy V Xiao ZS He N Zhou HH Wood AJJ: Frequency of endothelial nitric oxide synthase Glu298 Asp polymorphism varies among African-Americans (AA), Caucasians (CA) and Chinese (CH). Clinical Pharmacology and Therapeutics 67:125, 2000.
209. Xie HG Kim RB Dishy V Sofowora G Xiao ZS He N Zhou HH Wood AJJ Stein CM: Ethnic differences in beta-1 adrenoceptor (Bar 1) polymorphism (Gly389|Arg) frequency in African-American (AA), Caucasians (CA) and Chinese (CH). Clinical Pharmacology and Therapeutics 67:125, 2000.

210. Choo EF Wood AJJ Wilkinson GR Kim RB: Enhanced distribution of nelfinavir into brain and testes by pharmacologic inhibition of P-glycoprotein. Clinical Pharmacology and Therapeutics 67:114, 2000.
211. Dishy V Sofowora GG Xie HG Stein CM Kim RB Wood AJJ: Agonist-mediated vasodilation and desensitization *in vivo* is determined by  $\beta_2$ -adrenergic receptor polymorphisms. Circulation 102: Suppl. II:486, 2000.
212. Landau R Wood AJJ Dishy V Xie HG Emala C Smiley RM: Association of the Arg16Gly polymorphism of the  $\beta_2$ -adrenergic receptor with preterm labor. Anesthesiology April 2000, A6.
213. Landau R Wood AJJ Dishy V Xie HG Smiley RM: A Polymorphism of the endothelial nitric oxide synthase gene is associated with pre-eclampsia. Anesthesiology April 2000, A12.
214. Landau R Wood AJJ Dishy V Xie HG Emala C Smiley RM: Association of the Glu298Asp polymorphism of the endothelial nitric oxide synthase gene with preterm labor. Anesthesiology April 2000, A13.
215. Landau R Wood AJJ Dishy V Stein CM Smiley RM: Decreased vascular response to phenylephrine in pregnancy. Anesthesiology April 2000, A17.
216. Landau R Wood AJJ Dishy V Stein CM Smiley RM: Vascular response to isoproterenol in pregnancy. Anesthesiology April 2000, A33.
217. Kim RB Leake B Choo E Dresser GK Kubba SV Schwarz UI Taylor A Xie HG Stein CM Wood AJJ McKinsey J Schuetz EG Schuetz JD Wilkinson GR: Identification of functionally important MDR1 variant alleles among African-American and Caucasian subjects. Drug Metabolism Reviews 32:199, 2000.
218. Landau R Wood AJJ Dishy V Xie HG Smiley RM: Association of a polymorphism of the beta-2 adrenergic receptor with pre-eclampsia. Anesthesiology April 2000, A41.
219. Dishy V Sofowora G Imamura H Xie HG Stein CM Wood AJJ: Nitric oxide production decreases after salt loading but does not predict blood pressure responses. Clinical Pharmacology and Therapeutics 69:PI-16, 2001.
220. Dishy V Sofowora G Xie HG Harris P Wood AJJ Stein CM: Arg389Gly beta-1 adrenoceptor polymorphism does not affect agonist-mediated responses *in vivo*. Clinical Pharmacology and Therapeutics 69:PI-17, 2001.
221. Nishimi Y Shah AK Willavize SA McNeill SC Wood AJJ: Ethnicity and zopolrestat (Z) pharmacokinetics (PK) after multiple oral doses in normal, healthy Caucasian and Japanese subjects. Clinical Pharmacology and Therapeutics 69:PII-33, 2001.

222. Sofowora G Dishy V Wood AJJ Stein CM: Sildenafil potentiates the response to exogenous but not endogenous nitric oxide in the human hand vein. Clinical Pharmacology and Therapeutics 69:PIII-10, 2001.
223. Sofowora G Dishy V Roden D Wood AJJ Stein CM: The Effect of sildenafil on QT interval in healthy men. Clinical Pharmacology and Therapeutics 69:PIII-11, 2001.
224. Wandel C Kim RB Wood AJJ Stein CM: "Inactive" ingredients may alter bioavailability of drugs through effects on P-glycoprotein (PGP) and CYP3A. Clinical Pharmacology and Therapeutics 69:PIII-28, 2001.
225. Xie HG Sofowora G Dishy V Kim RB Wood AJJ Stein CM: Beta-1 and beta-2 adrenergic receptor (BAR) polymorphisms and obesity in African-Americans (AA) and Caucasian-Americans (CA). Clinical Pharmacology and Therapeutics 69:PIII-40, 2001.
226. Xie HG Dishy V Sofowora G Kim RB Wood AJJ Stein CM: Human beta-1 adrenergic receptor (BAR1) polymorphism (Arg389Gly) is not associated with essential hypertension in black or white Americans. Clinical Pharmacology and Therapeutics 69:PIII-41, 2001.
227. Gupta BA Dishy V Xie HG Landau R Smiley RM Wood AJJ Kim RB Stein CM: G-protein  $\beta$ -3 subunit 825C/T polymorphism is associated with weight gain in pregnancy but not with pre-eclampsia. Clinical Pharmacology and Therapeutics 69:PIII-45, 2001.
228. Smiley RM Landau R Dishy V Xie HG Wood AJ Kim RB Stein CM: Association of the G-protein  $\beta$ -3 subunit 825C/T polymorphism and weight gain in pregnancy. Anesthesiology 94:A49, 2001.
229. Xie H Prasad H Landau R Kim R Cai W Ieiri I Smiley R Wilkinson G Stein C Wood A: Frequency of the defective *CYP2C9* variant alleles in different ethnic groups. Clinical Pharmacology and Therapeutics 71:WP III-98, 2002.
230. Sofowora G Dishy V Xie H Kim R Harris P Mackanos M Prasad H Wood AJ Stein C: Beta-1 adrenoceptor genotype affects sensitivity to beta blocker. Clinical Pharmacology and Therapeutics 71:SOI-B-4, 2002.
231. Sofowora G Dishy V Xie HG Kim RB Harris P Mackanos M Wood AJJ Stein CM: Effect of beta-2 adrenoceptor polymorphisms on hemodynamic responses to exercise and mental stress. Clinical Pharmacology and Therapeutics 71:MPI-15, 2002.
232. Xie H Dishy V Sofowora G Landau R Kim R Cai W Smiley R Wood A Stein C: Frequency of a functionally important  $\beta$ 2-adrenergic receptor Thr<sup>164</sup>Ile polymorphism among different ethnic groups. Clinical Pharmacology and Therapeutics 71:WP III-95, 2002.
233. Sofowora G Dishy V Landau R Smiley R Xie H Kim R Wood A Stein C: Effect of  $\alpha_{1A}$  adrenergic receptor genotype on vascular response. Clinical Pharmacology and Therapeutics 71:MPI-16, 2002.

234. Dishy V Sofowora G Landau R Xie H Byrne D Smiley R Wood A Stein C: Balance of adrenergic vascular response is shifted towards enhanced vasodilation in premenopausal women. Clinical Pharmacology and Therapeutics 71:SOI-B-2, 2002.
235. Dishy V Harris P Pierce R Bonnar H Wood A Stein C: Sildenafil does not reverse endothelial dysfunction in smokers. Clinical Pharmacology and Therapeutics 71:MPI-14, 2002.
236. Caraco Y Kraselnikov I Wood AJ: Prediction of drug interaction with CYP2C9 substrates using phenytoin metabolic ratio. Clinical Pharmacology and Therapeutics 71:MPI-120, 2002.
237. Caraco Y Kraselnikov I Wood A: Repeated PMR is characterized by small intra-subject day to day variability in CYP2C9 activity. Clinical Pharmacology and Therapeutics 71:MPI-121, 2002.
238. Dishy V Landau Cahana R Sofowora G Xie H Smiley RM Kim RB Byrne DW Wood AJ Stein CM: Beta2 adrenoceptor Thr164Ile polymorphism is associated with markedly decreased vasodilator and increased vasoconstrictor sensitivity in vivo. Clinical Pharmacology and Therapeutics 73:PI-1, 2003.
239. Prasad HC Dishy V Sofowora G Muszkat M Kim RB Wood AJ Stein CM: A search for the genomic basis for interindividual variability in alpha1A-adrenergic receptor response. Clinical Pharmacology and Therapeutics 73:PI-2, 2003.
240. Muszkat M Sofowora G Wood AJJ Stein CM: Regulation of alpha2 adrenergic vascular responses in vivo. Clinical Pharmacology and Therapeutics 73:PI-3, 2003.
241. Muszkat M Sofowora G Dishy V Wood AJJ Stein CM: Effect of alpha2B adrenergic receptor 301-303 deletion polymorphism on blood pressure response to dietary sodium. Clinical Pharmacology and Therapeutics 73:PI-4, 2003.
242. Muszkat M Sofowora G Wood AJJ Stein CM: Alpha2 adrenergic receptor-mediated vascular responses in Africa-Americans and Caucasians. Clinical Pharmacology and Therapeutics 73:PI-5, 2003.
243. Xie HG Landau R Smiley RM Kim RB Wood AJJ Stein CM: A 9-base pair deletion polymorphism in the alpha2B-adrenergic receptor gene (ADRA2B) is not associated with pre-eclampsia or pre-term labor. Clinical Pharmacology and Therapeutics 73:PI-42, 2003.
244. Xie HG Muszkat M Sofowora G Landau R Cai WM Kim RB Smiley RM Stein CM Wood AJJ: Ethnic variability in the frequency of alpha2B-adrenergic receptor gene (ADRA2B) polymorphism. Clinical Pharmacology and Therapeutics 73:PI-43, 2003.

245. Sofowora G Muszkat M Dishy V Prasad HC Wood AJ Stein CM: Increased alpha1 adrenergic vascular sensitivity in the dorsal hand vein in African-Americans. Clinical Pharmacology and Therapeutics 73:OII-B-1, 2003.
246. Prasad HC Kim RB Wood AJJ Stein CM: Identification of a new beta1-adrenergic receptor variant Val5Ala more frequent in African-Americans. Clinical Pharmacology and Therapeutics 73:PDII-C-5, 2003.
247. Sofowora GG Dishy V Muszkat M Xie H Prasad HC Wood AJ Stein CM: Beta-2 adrenergic receptor polymorphisms and blood pressure responses to salt. Clinical Pharmacology and Therapeutics 75:PI-38, 2004.
248. Muszkat M Sofowora G Dishy V Xie H Harris PA Wood AJ Stein C: Effect of alpha-2C adrenergic receptor (ADRA2C) 322-325 deletion polymorphism on blood pressure response to dietary sodium in African-Americans (AA). Clinical Pharmacology and Therapeutics 75:PI-39, 2004.
249. Muszkat M Sofowora G Xie H Wood AJ Stein C: Alpha-2C adrenergic receptor (ADRA2C) 322-325 deletion polymorphism and in vivo vascular sensitivity. Clinical Pharmacology and Therapeutics 75:PII-11, 2004.
250. Xie H Landau R Dishy V Sofowora GG Smiley RM Kim RB Wood AJ Stein CM: A common polymorphism in the adenylyl cyclase type 9 (AC9) gene does not alter vascular responses to isoproterenol. Clinical Pharmacology and Therapeutics 75:PII-67, 2004.
251. Muszkat M Sofowora G Xie H Harris PA Wood AJ Stein C: Alpha-2B adrenergic receptor (ADRA2B) 301-303 deletion polymorphism and vascular desensitization in vivo. Clinical Pharmacology and Therapeutics 75:PDII-A-10, 2004.